livn-20250930
false
12/31
2025
Q3
0001639691
xbrli:shares
iso4217:USD
iso4217:USD
xbrli:shares
iso4217:GBP
xbrli:shares
xbrli:pure
iso4217:EUR
livn:claim
livn:lawsuit
livn:segment
livn:region
0001639691
2025-01-01
2025-09-30
0001639691
2025-10-29
0001639691
2025-07-01
2025-09-30
0001639691
2024-07-01
2024-09-30
0001639691
2024-01-01
2024-09-30
0001639691
2025-09-30
0001639691
2024-12-31
0001639691
2023-12-31
0001639691
2024-09-30
0001639691
livn:CybersecurityIncidentMember
2023-11-01
2025-09-30
0001639691
livn:CybersecurityIncidentMember
2025-07-01
2025-09-30
0001639691
livn:CybersecurityIncidentMember
2024-07-01
2024-09-30
0001639691
livn:CybersecurityIncidentMember
2025-01-01
2025-09-30
0001639691
livn:CybersecurityIncidentMember
2024-01-01
2024-09-30
0001639691
us-gaap:PendingLitigationMember
livn:CyberLitigationMember
2023-11-01
2025-09-30
0001639691
livn:CyberLitigationMember
2023-11-01
2025-09-30
0001639691
livn:CyberLitigationMember
2025-01-01
2025-09-30
0001639691
us-gaap:ForeignExchangeContractMember
us-gaap:NondesignatedMember
2025-09-30
0001639691
us-gaap:ForeignExchangeContractMember
us-gaap:NondesignatedMember
2024-12-31
0001639691
us-gaap:ForeignExchangeContractMember
2025-07-01
2025-09-30
0001639691
us-gaap:ForeignExchangeContractMember
2024-07-01
2024-09-30
0001639691
us-gaap:ForeignExchangeContractMember
2025-01-01
2025-09-30
0001639691
us-gaap:ForeignExchangeContractMember
2024-01-01
2024-09-30
0001639691
livn:CappedCallMember
us-gaap:NondesignatedMember
livn:A2025NotesMember
2025-09-30
0001639691
livn:CappedCallMember
us-gaap:NondesignatedMember
livn:A2029NotesMember
2025-09-30
0001639691
us-gaap:EmbeddedDerivativeFinancialInstrumentsMember
us-gaap:NondesignatedMember
livn:A2025NotesMember
2025-09-30
0001639691
us-gaap:EmbeddedDerivativeFinancialInstrumentsMember
us-gaap:NondesignatedMember
livn:A2029NotesMember
2025-09-30
0001639691
us-gaap:NondesignatedMember
2025-09-30
0001639691
livn:CappedCallMember
us-gaap:NondesignatedMember
livn:A2025NotesMember
2024-12-31
0001639691
livn:CappedCallMember
us-gaap:NondesignatedMember
livn:A2029NotesMember
2024-12-31
0001639691
us-gaap:EmbeddedDerivativeFinancialInstrumentsMember
us-gaap:NondesignatedMember
livn:A2025NotesMember
2024-12-31
0001639691
us-gaap:EmbeddedDerivativeFinancialInstrumentsMember
us-gaap:NondesignatedMember
livn:A2029NotesMember
2024-12-31
0001639691
us-gaap:NondesignatedMember
2024-12-31
0001639691
livn:CappedCallMember
us-gaap:FairValueMeasurementsRecurringMember
livn:A2025NotesMember
2025-09-30
0001639691
livn:CappedCallMember
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:FairValueInputsLevel1Member
livn:A2025NotesMember
2025-09-30
0001639691
livn:CappedCallMember
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:FairValueInputsLevel2Member
livn:A2025NotesMember
2025-09-30
0001639691
livn:CappedCallMember
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:FairValueInputsLevel3Member
livn:A2025NotesMember
2025-09-30
0001639691
livn:CappedCallMember
us-gaap:FairValueMeasurementsRecurringMember
livn:A2029NotesMember
2025-09-30
0001639691
livn:CappedCallMember
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:FairValueInputsLevel1Member
livn:A2029NotesMember
2025-09-30
0001639691
livn:CappedCallMember
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:FairValueInputsLevel2Member
livn:A2029NotesMember
2025-09-30
0001639691
livn:CappedCallMember
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:FairValueInputsLevel3Member
livn:A2029NotesMember
2025-09-30
0001639691
us-gaap:FairValueMeasurementsRecurringMember
2025-09-30
0001639691
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:FairValueInputsLevel1Member
2025-09-30
0001639691
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:FairValueInputsLevel2Member
2025-09-30
0001639691
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:FairValueInputsLevel3Member
2025-09-30
0001639691
us-gaap:ForeignExchangeContractMember
us-gaap:FairValueMeasurementsRecurringMember
2025-09-30
0001639691
us-gaap:ForeignExchangeContractMember
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:FairValueInputsLevel1Member
2025-09-30
0001639691
us-gaap:ForeignExchangeContractMember
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:FairValueInputsLevel2Member
2025-09-30
0001639691
us-gaap:ForeignExchangeContractMember
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:FairValueInputsLevel3Member
2025-09-30
0001639691
us-gaap:EmbeddedDerivativeFinancialInstrumentsMember
us-gaap:FairValueMeasurementsRecurringMember
livn:A2025NotesMember
2025-09-30
0001639691
us-gaap:EmbeddedDerivativeFinancialInstrumentsMember
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:FairValueInputsLevel1Member
livn:A2025NotesMember
2025-09-30
0001639691
us-gaap:EmbeddedDerivativeFinancialInstrumentsMember
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:FairValueInputsLevel2Member
livn:A2025NotesMember
2025-09-30
0001639691
us-gaap:EmbeddedDerivativeFinancialInstrumentsMember
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:FairValueInputsLevel3Member
livn:A2025NotesMember
2025-09-30
0001639691
us-gaap:EmbeddedDerivativeFinancialInstrumentsMember
us-gaap:FairValueMeasurementsRecurringMember
livn:A2029NotesMember
2025-09-30
0001639691
us-gaap:EmbeddedDerivativeFinancialInstrumentsMember
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:FairValueInputsLevel1Member
livn:A2029NotesMember
2025-09-30
0001639691
us-gaap:EmbeddedDerivativeFinancialInstrumentsMember
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:FairValueInputsLevel2Member
livn:A2029NotesMember
2025-09-30
0001639691
us-gaap:EmbeddedDerivativeFinancialInstrumentsMember
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:FairValueInputsLevel3Member
livn:A2029NotesMember
2025-09-30
0001639691
us-gaap:ForeignExchangeContractMember
us-gaap:FairValueMeasurementsRecurringMember
2024-12-31
0001639691
us-gaap:ForeignExchangeContractMember
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:FairValueInputsLevel1Member
2024-12-31
0001639691
us-gaap:ForeignExchangeContractMember
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:FairValueInputsLevel2Member
2024-12-31
0001639691
us-gaap:ForeignExchangeContractMember
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:FairValueInputsLevel3Member
2024-12-31
0001639691
livn:CappedCallMember
us-gaap:FairValueMeasurementsRecurringMember
livn:A2025NotesMember
2024-12-31
0001639691
livn:CappedCallMember
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:FairValueInputsLevel1Member
livn:A2025NotesMember
2024-12-31
0001639691
livn:CappedCallMember
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:FairValueInputsLevel2Member
livn:A2025NotesMember
2024-12-31
0001639691
livn:CappedCallMember
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:FairValueInputsLevel3Member
livn:A2025NotesMember
2024-12-31
0001639691
livn:CappedCallMember
us-gaap:FairValueMeasurementsRecurringMember
livn:A2029NotesMember
2024-12-31
0001639691
livn:CappedCallMember
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:FairValueInputsLevel1Member
livn:A2029NotesMember
2024-12-31
0001639691
livn:CappedCallMember
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:FairValueInputsLevel2Member
livn:A2029NotesMember
2024-12-31
0001639691
livn:CappedCallMember
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:FairValueInputsLevel3Member
livn:A2029NotesMember
2024-12-31
0001639691
us-gaap:FairValueMeasurementsRecurringMember
2024-12-31
0001639691
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:FairValueInputsLevel1Member
2024-12-31
0001639691
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:FairValueInputsLevel2Member
2024-12-31
0001639691
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:FairValueInputsLevel3Member
2024-12-31
0001639691
us-gaap:EmbeddedDerivativeFinancialInstrumentsMember
us-gaap:FairValueMeasurementsRecurringMember
livn:A2025NotesMember
2024-12-31
0001639691
us-gaap:EmbeddedDerivativeFinancialInstrumentsMember
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:FairValueInputsLevel1Member
livn:A2025NotesMember
2024-12-31
0001639691
us-gaap:EmbeddedDerivativeFinancialInstrumentsMember
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:FairValueInputsLevel2Member
livn:A2025NotesMember
2024-12-31
0001639691
us-gaap:EmbeddedDerivativeFinancialInstrumentsMember
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:FairValueInputsLevel3Member
livn:A2025NotesMember
2024-12-31
0001639691
us-gaap:EmbeddedDerivativeFinancialInstrumentsMember
us-gaap:FairValueMeasurementsRecurringMember
livn:A2029NotesMember
2024-12-31
0001639691
us-gaap:EmbeddedDerivativeFinancialInstrumentsMember
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:FairValueInputsLevel1Member
livn:A2029NotesMember
2024-12-31
0001639691
us-gaap:EmbeddedDerivativeFinancialInstrumentsMember
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:FairValueInputsLevel2Member
livn:A2029NotesMember
2024-12-31
0001639691
us-gaap:EmbeddedDerivativeFinancialInstrumentsMember
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:FairValueInputsLevel3Member
livn:A2029NotesMember
2024-12-31
0001639691
livn:CappedCallMember
us-gaap:DerivativeFinancialInstrumentsAssetsMember
us-gaap:FairValueMeasurementsRecurringMember
livn:A2025NotesMember
2025-06-30
0001639691
livn:CappedCallMember
us-gaap:DerivativeFinancialInstrumentsAssetsMember
us-gaap:FairValueMeasurementsRecurringMember
livn:A2029NotesMember
2025-06-30
0001639691
us-gaap:EmbeddedDerivativeFinancialInstrumentsMember
us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember
us-gaap:FairValueMeasurementsRecurringMember
livn:A2025NotesMember
2025-06-30
0001639691
us-gaap:EmbeddedDerivativeFinancialInstrumentsMember
us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember
us-gaap:FairValueMeasurementsRecurringMember
livn:A2029NotesMember
2025-06-30
0001639691
livn:ContingentConsiderationLiabilityMember
us-gaap:FairValueMeasurementsRecurringMember
2025-06-30
0001639691
livn:CappedCallMember
us-gaap:DerivativeFinancialInstrumentsAssetsMember
us-gaap:FairValueMeasurementsRecurringMember
livn:A2025NotesMember
2025-07-01
2025-09-30
0001639691
livn:CappedCallMember
us-gaap:DerivativeFinancialInstrumentsAssetsMember
us-gaap:FairValueMeasurementsRecurringMember
livn:A2029NotesMember
2025-07-01
2025-09-30
0001639691
us-gaap:EmbeddedDerivativeFinancialInstrumentsMember
us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember
us-gaap:FairValueMeasurementsRecurringMember
livn:A2025NotesMember
2025-07-01
2025-09-30
0001639691
us-gaap:EmbeddedDerivativeFinancialInstrumentsMember
us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember
us-gaap:FairValueMeasurementsRecurringMember
livn:A2029NotesMember
2025-07-01
2025-09-30
0001639691
livn:ContingentConsiderationLiabilityMember
us-gaap:FairValueMeasurementsRecurringMember
2025-07-01
2025-09-30
0001639691
livn:CappedCallMember
us-gaap:DerivativeFinancialInstrumentsAssetsMember
us-gaap:FairValueMeasurementsRecurringMember
livn:A2025NotesMember
2025-09-30
0001639691
livn:CappedCallMember
us-gaap:DerivativeFinancialInstrumentsAssetsMember
us-gaap:FairValueMeasurementsRecurringMember
livn:A2029NotesMember
2025-09-30
0001639691
us-gaap:EmbeddedDerivativeFinancialInstrumentsMember
us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember
us-gaap:FairValueMeasurementsRecurringMember
livn:A2025NotesMember
2025-09-30
0001639691
us-gaap:EmbeddedDerivativeFinancialInstrumentsMember
us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember
us-gaap:FairValueMeasurementsRecurringMember
livn:A2029NotesMember
2025-09-30
0001639691
livn:ContingentConsiderationLiabilityMember
us-gaap:FairValueMeasurementsRecurringMember
2025-09-30
0001639691
livn:CappedCallMember
us-gaap:DerivativeFinancialInstrumentsAssetsMember
us-gaap:FairValueMeasurementsRecurringMember
livn:A2025NotesMember
2024-06-30
0001639691
livn:CappedCallMember
us-gaap:DerivativeFinancialInstrumentsAssetsMember
us-gaap:FairValueMeasurementsRecurringMember
livn:A2029NotesMember
2024-06-30
0001639691
us-gaap:NotesReceivableMember
us-gaap:FairValueMeasurementsRecurringMember
2024-06-30
0001639691
us-gaap:EmbeddedDerivativeFinancialInstrumentsMember
us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember
us-gaap:FairValueMeasurementsRecurringMember
livn:A2025NotesMember
2024-06-30
0001639691
us-gaap:EmbeddedDerivativeFinancialInstrumentsMember
us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember
us-gaap:FairValueMeasurementsRecurringMember
livn:A2029NotesMember
2024-06-30
0001639691
livn:ContingentConsiderationLiabilityMember
us-gaap:FairValueMeasurementsRecurringMember
2024-06-30
0001639691
livn:CappedCallMember
us-gaap:DerivativeFinancialInstrumentsAssetsMember
us-gaap:FairValueMeasurementsRecurringMember
livn:A2025NotesMember
2024-07-01
2024-09-30
0001639691
livn:CappedCallMember
us-gaap:DerivativeFinancialInstrumentsAssetsMember
us-gaap:FairValueMeasurementsRecurringMember
livn:A2029NotesMember
2024-07-01
2024-09-30
0001639691
us-gaap:NotesReceivableMember
us-gaap:FairValueMeasurementsRecurringMember
2024-07-01
2024-09-30
0001639691
us-gaap:EmbeddedDerivativeFinancialInstrumentsMember
us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember
us-gaap:FairValueMeasurementsRecurringMember
livn:A2025NotesMember
2024-07-01
2024-09-30
0001639691
us-gaap:EmbeddedDerivativeFinancialInstrumentsMember
us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember
us-gaap:FairValueMeasurementsRecurringMember
livn:A2029NotesMember
2024-07-01
2024-09-30
0001639691
livn:ContingentConsiderationLiabilityMember
us-gaap:FairValueMeasurementsRecurringMember
2024-07-01
2024-09-30
0001639691
livn:CappedCallMember
us-gaap:DerivativeFinancialInstrumentsAssetsMember
us-gaap:FairValueMeasurementsRecurringMember
livn:A2025NotesMember
2024-09-30
0001639691
livn:CappedCallMember
us-gaap:DerivativeFinancialInstrumentsAssetsMember
us-gaap:FairValueMeasurementsRecurringMember
livn:A2029NotesMember
2024-09-30
0001639691
us-gaap:NotesReceivableMember
us-gaap:FairValueMeasurementsRecurringMember
2024-09-30
0001639691
us-gaap:EmbeddedDerivativeFinancialInstrumentsMember
us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember
us-gaap:FairValueMeasurementsRecurringMember
livn:A2025NotesMember
2024-09-30
0001639691
us-gaap:EmbeddedDerivativeFinancialInstrumentsMember
us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember
us-gaap:FairValueMeasurementsRecurringMember
livn:A2029NotesMember
2024-09-30
0001639691
livn:ContingentConsiderationLiabilityMember
us-gaap:FairValueMeasurementsRecurringMember
2024-09-30
0001639691
livn:CappedCallMember
us-gaap:DerivativeFinancialInstrumentsAssetsMember
us-gaap:FairValueMeasurementsRecurringMember
livn:A2025NotesMember
2024-12-31
0001639691
livn:CappedCallMember
us-gaap:DerivativeFinancialInstrumentsAssetsMember
us-gaap:FairValueMeasurementsRecurringMember
livn:A2029NotesMember
2024-12-31
0001639691
us-gaap:EmbeddedDerivativeFinancialInstrumentsMember
us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember
us-gaap:FairValueMeasurementsRecurringMember
livn:A2025NotesMember
2024-12-31
0001639691
us-gaap:EmbeddedDerivativeFinancialInstrumentsMember
us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember
us-gaap:FairValueMeasurementsRecurringMember
livn:A2029NotesMember
2024-12-31
0001639691
livn:ContingentConsiderationLiabilityMember
us-gaap:FairValueMeasurementsRecurringMember
2024-12-31
0001639691
livn:CappedCallMember
us-gaap:DerivativeFinancialInstrumentsAssetsMember
us-gaap:FairValueMeasurementsRecurringMember
livn:A2025NotesMember
2025-01-01
2025-09-30
0001639691
livn:CappedCallMember
us-gaap:DerivativeFinancialInstrumentsAssetsMember
us-gaap:FairValueMeasurementsRecurringMember
livn:A2029NotesMember
2025-01-01
2025-09-30
0001639691
us-gaap:EmbeddedDerivativeFinancialInstrumentsMember
us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember
us-gaap:FairValueMeasurementsRecurringMember
livn:A2025NotesMember
2025-01-01
2025-09-30
0001639691
us-gaap:EmbeddedDerivativeFinancialInstrumentsMember
us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember
us-gaap:FairValueMeasurementsRecurringMember
livn:A2029NotesMember
2025-01-01
2025-09-30
0001639691
livn:ContingentConsiderationLiabilityMember
us-gaap:FairValueMeasurementsRecurringMember
2025-01-01
2025-09-30
0001639691
livn:CappedCallMember
us-gaap:DerivativeFinancialInstrumentsAssetsMember
us-gaap:FairValueMeasurementsRecurringMember
livn:A2025NotesMember
2023-12-31
0001639691
livn:CappedCallMember
us-gaap:DerivativeFinancialInstrumentsAssetsMember
us-gaap:FairValueMeasurementsRecurringMember
livn:A2029NotesMember
2023-12-31
0001639691
us-gaap:NotesReceivableMember
us-gaap:FairValueMeasurementsRecurringMember
2023-12-31
0001639691
us-gaap:EmbeddedDerivativeFinancialInstrumentsMember
us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember
us-gaap:FairValueMeasurementsRecurringMember
livn:A2025NotesMember
2023-12-31
0001639691
us-gaap:EmbeddedDerivativeFinancialInstrumentsMember
us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember
us-gaap:FairValueMeasurementsRecurringMember
livn:A2029NotesMember
2023-12-31
0001639691
livn:ContingentConsiderationLiabilityMember
us-gaap:FairValueMeasurementsRecurringMember
2023-12-31
0001639691
livn:CappedCallMember
us-gaap:DerivativeFinancialInstrumentsAssetsMember
us-gaap:FairValueMeasurementsRecurringMember
livn:A2025NotesMember
2024-01-01
2024-09-30
0001639691
livn:CappedCallMember
us-gaap:DerivativeFinancialInstrumentsAssetsMember
us-gaap:FairValueMeasurementsRecurringMember
livn:A2029NotesMember
2024-01-01
2024-09-30
0001639691
us-gaap:NotesReceivableMember
us-gaap:FairValueMeasurementsRecurringMember
2024-01-01
2024-09-30
0001639691
us-gaap:EmbeddedDerivativeFinancialInstrumentsMember
us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember
us-gaap:FairValueMeasurementsRecurringMember
livn:A2025NotesMember
2024-01-01
2024-09-30
0001639691
us-gaap:EmbeddedDerivativeFinancialInstrumentsMember
us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember
us-gaap:FairValueMeasurementsRecurringMember
livn:A2029NotesMember
2024-01-01
2024-09-30
0001639691
livn:ContingentConsiderationLiabilityMember
us-gaap:FairValueMeasurementsRecurringMember
2024-01-01
2024-09-30
0001639691
livn:CappedCallMember
livn:A2025NotesMember
us-gaap:MeasurementInputPriceVolatilityMember
2025-09-30
0001639691
livn:CappedCallMember
livn:A2029NotesMember
us-gaap:MeasurementInputPriceVolatilityMember
2025-09-30
0001639691
us-gaap:EmbeddedDerivativeFinancialInstrumentsMember
livn:A2025NotesMember
us-gaap:MeasurementInputPriceVolatilityMember
2025-09-30
0001639691
us-gaap:EmbeddedDerivativeFinancialInstrumentsMember
livn:A2029NotesMember
us-gaap:MeasurementInputPriceVolatilityMember
2025-09-30
0001639691
livn:CappedCallMember
livn:A2025NotesMember
us-gaap:MeasurementInputPriceVolatilityMember
2024-12-31
0001639691
livn:CappedCallMember
livn:A2029NotesMember
us-gaap:MeasurementInputPriceVolatilityMember
2024-12-31
0001639691
us-gaap:EmbeddedDerivativeFinancialInstrumentsMember
livn:A2025NotesMember
us-gaap:MeasurementInputPriceVolatilityMember
2024-12-31
0001639691
us-gaap:EmbeddedDerivativeFinancialInstrumentsMember
livn:A2029NotesMember
us-gaap:MeasurementInputPriceVolatilityMember
2024-12-31
0001639691
livn:ImTheraMedicalInc.Member
us-gaap:FairValueInputsLevel3Member
us-gaap:ValuationTechniqueDiscountedCashFlowMember
us-gaap:MeasurementInputDiscountRateMember
2025-09-30
0001639691
livn:ImTheraMedicalInc.Member
us-gaap:FairValueInputsLevel3Member
us-gaap:ValuationTechniqueDiscountedCashFlowMember
livn:MeasurementInputProbabilityofPaymentMember
2025-09-30
0001639691
livn:ImTheraMedicalInc.Member
livn:MeasurementInputRiskadjustedDiscountRateMember
us-gaap:FairValueInputsLevel3Member
us-gaap:MonteCarloModelMember
srt:MinimumMember
2025-09-30
0001639691
livn:ImTheraMedicalInc.Member
livn:MeasurementInputRiskadjustedDiscountRateMember
us-gaap:FairValueInputsLevel3Member
us-gaap:MonteCarloModelMember
srt:MaximumMember
2025-09-30
0001639691
livn:ImTheraMedicalInc.Member
livn:MeasurementInputCreditRiskDiscountRateMember
us-gaap:FairValueInputsLevel3Member
us-gaap:MonteCarloModelMember
srt:MinimumMember
2025-09-30
0001639691
livn:ImTheraMedicalInc.Member
livn:MeasurementInputCreditRiskDiscountRateMember
us-gaap:FairValueInputsLevel3Member
us-gaap:MonteCarloModelMember
srt:MaximumMember
2025-09-30
0001639691
livn:ImTheraMedicalInc.Member
us-gaap:FairValueInputsLevel3Member
us-gaap:MonteCarloModelMember
livn:MeasurementInputRevenueVolatilityMember
2025-09-30
0001639691
livn:ImTheraMedicalInc.Member
us-gaap:FairValueInputsLevel3Member
us-gaap:MonteCarloModelMember
livn:MeasurementInputProbabilityofPaymentMember
2025-09-30
0001639691
livn:TermLoanMember
2025-09-30
0001639691
livn:TermLoanMember
2024-12-31
0001639691
livn:A2029NotesMember
us-gaap:SeniorNotesMember
2025-09-30
0001639691
livn:A2029NotesMember
us-gaap:SeniorNotesMember
2024-12-31
0001639691
livn:A2025NotesMember
us-gaap:SeniorNotesMember
2025-09-30
0001639691
livn:A2025NotesMember
us-gaap:SeniorNotesMember
2024-12-31
0001639691
livn:BankofAmericaU.SMember
us-gaap:LoansPayableMember
2025-09-30
0001639691
livn:BankofAmericaU.SMember
us-gaap:LoansPayableMember
2024-12-31
0001639691
us-gaap:OtherDebtSecuritiesMember
2025-09-30
0001639691
us-gaap:OtherDebtSecuritiesMember
2024-12-31
0001639691
us-gaap:RevolvingCreditFacilityMember
2025-09-30
0001639691
us-gaap:RevolvingCreditFacilityMember
2024-12-31
0001639691
us-gaap:RevolvingCreditFacilityMember
2025-09-30
0001639691
us-gaap:RevolvingCreditFacilityMember
2024-12-31
0001639691
2024-01-01
2024-12-31
0001639691
us-gaap:RevolvingCreditFacilityMember
us-gaap:LineOfCreditMember
2022-07-06
0001639691
us-gaap:RevolvingCreditFacilityMember
us-gaap:LineOfCreditMember
2025-09-30
0001639691
us-gaap:RevolvingCreditFacilityMember
us-gaap:LineOfCreditMember
2024-12-31
0001639691
livn:TermLoanMember
2025-05-02
2025-05-02
0001639691
livn:TermLoanMember
2025-01-01
2025-09-30
0001639691
livn:SaluggiaItalyMember
2020-01-01
2020-12-31
0001639691
livn:SaluggiaItalyMember
srt:MinimumMember
2025-09-30
0001639691
livn:SaluggiaItalyMember
srt:MaximumMember
2025-09-30
0001639691
livn:SaluggiaItalyMember
2024-12-31
0001639691
us-gaap:PendingLitigationMember
livn:SNIAMember
livn:SNIAs.p.aMember
2025-01-01
2025-09-30
0001639691
us-gaap:PendingLitigationMember
livn:SNIAMember
livn:SNIAs.p.aMember
2025-09-30
0001639691
2016-01-01
2016-12-31
0001639691
us-gaap:JudicialRulingMember
2019-03-05
0001639691
us-gaap:PendingLitigationMember
2025-09-30
0001639691
us-gaap:JudicialRulingMember
livn:SNIAMember
2021-12-31
0001639691
us-gaap:JudicialRulingMember
livn:SNIAMember
us-gaap:SuretyBondMember
2022-02-21
2022-02-21
0001639691
us-gaap:JudicialRulingMember
livn:SNIAMember
us-gaap:SuretyBondMember
2025-01-01
2025-09-30
0001639691
us-gaap:JudicialRulingMember
livn:SNIAMember
2022-02-21
2022-02-21
0001639691
livn:SNIAMember
2025-01-01
2025-09-30
0001639691
livn:SNIAMember
2025-09-30
0001639691
livn:ProductLiabilityMember
us-gaap:SubsequentEventMember
2025-11-05
0001639691
livn:ProductLiabilityMember
2025-07-01
2025-09-30
0001639691
livn:ProductLiabilityMember
2025-01-01
2025-09-30
0001639691
livn:ProductLiabilityMember
2025-09-30
0001639691
livn:ProductLiabilityMember
2024-12-31
0001639691
us-gaap:PendingLitigationMember
livn:ItalianMedTechPaybackMember
2025-09-01
2025-09-30
0001639691
us-gaap:PendingLitigationMember
livn:ItalianMedTechPaybackMember
2025-09-30
0001639691
us-gaap:PendingLitigationMember
livn:ItalianMedTechPaybackMember
2024-12-31
0001639691
us-gaap:PendingLitigationMember
livn:ItalianMedTechPayback20152018SettlementMember
2024-12-31
0001639691
us-gaap:PendingLitigationMember
livn:CyberLitigationMember
2025-09-30
0001639691
us-gaap:PendingLitigationMember
livn:CyberLitigationMember
2024-09-30
0001639691
us-gaap:CommonStockMember
2025-06-30
0001639691
us-gaap:AdditionalPaidInCapitalMember
2025-06-30
0001639691
us-gaap:TreasuryStockCommonMember
2025-06-30
0001639691
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2025-06-30
0001639691
us-gaap:RetainedEarningsMember
2025-06-30
0001639691
2025-06-30
0001639691
us-gaap:CommonStockMember
2025-07-01
2025-09-30
0001639691
us-gaap:AdditionalPaidInCapitalMember
2025-07-01
2025-09-30
0001639691
us-gaap:TreasuryStockCommonMember
2025-07-01
2025-09-30
0001639691
us-gaap:RetainedEarningsMember
2025-07-01
2025-09-30
0001639691
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2025-07-01
2025-09-30
0001639691
us-gaap:CommonStockMember
2025-09-30
0001639691
us-gaap:AdditionalPaidInCapitalMember
2025-09-30
0001639691
us-gaap:TreasuryStockCommonMember
2025-09-30
0001639691
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2025-09-30
0001639691
us-gaap:RetainedEarningsMember
2025-09-30
0001639691
us-gaap:CommonStockMember
2024-06-30
0001639691
us-gaap:AdditionalPaidInCapitalMember
2024-06-30
0001639691
us-gaap:TreasuryStockCommonMember
2024-06-30
0001639691
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2024-06-30
0001639691
us-gaap:RetainedEarningsMember
2024-06-30
0001639691
2024-06-30
0001639691
us-gaap:CommonStockMember
2024-07-01
2024-09-30
0001639691
us-gaap:AdditionalPaidInCapitalMember
2024-07-01
2024-09-30
0001639691
us-gaap:TreasuryStockCommonMember
2024-07-01
2024-09-30
0001639691
us-gaap:RetainedEarningsMember
2024-07-01
2024-09-30
0001639691
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2024-07-01
2024-09-30
0001639691
us-gaap:CommonStockMember
2024-09-30
0001639691
us-gaap:AdditionalPaidInCapitalMember
2024-09-30
0001639691
us-gaap:TreasuryStockCommonMember
2024-09-30
0001639691
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2024-09-30
0001639691
us-gaap:RetainedEarningsMember
2024-09-30
0001639691
us-gaap:CommonStockMember
2024-12-31
0001639691
us-gaap:AdditionalPaidInCapitalMember
2024-12-31
0001639691
us-gaap:TreasuryStockCommonMember
2024-12-31
0001639691
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2024-12-31
0001639691
us-gaap:RetainedEarningsMember
2024-12-31
0001639691
us-gaap:CommonStockMember
2025-01-01
2025-09-30
0001639691
us-gaap:TreasuryStockCommonMember
2025-01-01
2025-09-30
0001639691
us-gaap:AdditionalPaidInCapitalMember
2025-01-01
2025-09-30
0001639691
us-gaap:RetainedEarningsMember
2025-01-01
2025-09-30
0001639691
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2025-01-01
2025-09-30
0001639691
us-gaap:CommonStockMember
2023-12-31
0001639691
us-gaap:AdditionalPaidInCapitalMember
2023-12-31
0001639691
us-gaap:TreasuryStockCommonMember
2023-12-31
0001639691
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2023-12-31
0001639691
us-gaap:RetainedEarningsMember
2023-12-31
0001639691
us-gaap:CommonStockMember
2024-01-01
2024-09-30
0001639691
us-gaap:TreasuryStockCommonMember
2024-01-01
2024-09-30
0001639691
us-gaap:AdditionalPaidInCapitalMember
2024-01-01
2024-09-30
0001639691
us-gaap:RetainedEarningsMember
2024-01-01
2024-09-30
0001639691
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2024-01-01
2024-09-30
0001639691
us-gaap:AccumulatedTranslationAdjustmentMember
2024-12-31
0001639691
us-gaap:AccumulatedTranslationAdjustmentMember
2025-01-01
2025-09-30
0001639691
us-gaap:AccumulatedTranslationAdjustmentMember
2025-09-30
0001639691
us-gaap:AccumulatedTranslationAdjustmentMember
2023-12-31
0001639691
us-gaap:AccumulatedTranslationAdjustmentMember
2024-01-01
2024-09-30
0001639691
us-gaap:AccumulatedTranslationAdjustmentMember
2024-09-30
0001639691
livn:A2025DirectorIncentivePlanMember
2025-09-30
0001639691
livn:SecondAR2022PlanMember
2025-09-30
0001639691
us-gaap:RestrictedStockUnitsRSUMember
2025-01-01
2025-09-30
0001639691
us-gaap:StockAppreciationRightsSARSMember
2025-01-01
2025-09-30
0001639691
livn:MarketbasedPerformanceRestrictedStockUnitsMember
2025-01-01
2025-09-30
0001639691
srt:BoardOfDirectorsChairmanMember
us-gaap:RestrictedStockUnitsRSUMember
2025-01-01
2025-09-30
0001639691
livn:AwardYear2025Member
2025-07-01
2025-09-30
0001639691
livn:AwardYear2025Member
2025-01-01
2025-09-30
0001639691
livn:ServiceBasedRestrictedStockUnitsMember
2025-07-01
2025-09-30
0001639691
livn:ServiceBasedRestrictedStockUnitsMember
2024-07-01
2024-09-30
0001639691
livn:ServiceBasedRestrictedStockUnitsMember
2025-01-01
2025-09-30
0001639691
livn:ServiceBasedRestrictedStockUnitsMember
2024-01-01
2024-09-30
0001639691
livn:ServiceBasedStockAppreciationRightsMember
2025-07-01
2025-09-30
0001639691
livn:ServiceBasedStockAppreciationRightsMember
2024-07-01
2024-09-30
0001639691
livn:ServiceBasedStockAppreciationRightsMember
2025-01-01
2025-09-30
0001639691
livn:ServiceBasedStockAppreciationRightsMember
2024-01-01
2024-09-30
0001639691
livn:MarketbasedPerformanceRestrictedStockUnitsMember
2025-07-01
2025-09-30
0001639691
livn:MarketbasedPerformanceRestrictedStockUnitsMember
2024-07-01
2024-09-30
0001639691
livn:MarketbasedPerformanceRestrictedStockUnitsMember
2024-01-01
2024-09-30
0001639691
livn:PerformanceBasedRestrictedShareAndRestrictedShareUnitMember
2025-07-01
2025-09-30
0001639691
livn:PerformanceBasedRestrictedShareAndRestrictedShareUnitMember
2024-07-01
2024-09-30
0001639691
livn:PerformanceBasedRestrictedShareAndRestrictedShareUnitMember
2025-01-01
2025-09-30
0001639691
livn:PerformanceBasedRestrictedShareAndRestrictedShareUnitMember
2024-01-01
2024-09-30
0001639691
us-gaap:EmployeeStockMember
2025-07-01
2025-09-30
0001639691
us-gaap:EmployeeStockMember
2024-07-01
2024-09-30
0001639691
us-gaap:EmployeeStockMember
2025-01-01
2025-09-30
0001639691
us-gaap:EmployeeStockMember
2024-01-01
2024-09-30
0001639691
livn:ServiceBasedStockAppreciationRightsMember
2025-09-30
0001639691
livn:ServiceBasedRestrictedStockUnitsMember
2025-09-30
0001639691
livn:MarketbasedPerformanceRestrictedStockUnitsMember
2025-09-30
0001639691
livn:PerformanceBasedRestrictedShareAndRestrictedShareUnitMember
2025-09-30
0001639691
us-gaap:StockCompensationPlanMember
2025-07-01
2025-09-30
0001639691
us-gaap:StockCompensationPlanMember
2024-07-01
2024-09-30
0001639691
us-gaap:StockCompensationPlanMember
2025-01-01
2025-09-30
0001639691
us-gaap:StockCompensationPlanMember
2024-01-01
2024-09-30
0001639691
us-gaap:OperatingSegmentsMember
country:US
livn:CardiopulmonarySegmentMember
2025-07-01
2025-09-30
0001639691
us-gaap:OperatingSegmentsMember
country:US
livn:CardiopulmonarySegmentMember
2024-07-01
2024-09-30
0001639691
us-gaap:OperatingSegmentsMember
country:US
livn:CardiopulmonarySegmentMember
2025-01-01
2025-09-30
0001639691
us-gaap:OperatingSegmentsMember
country:US
livn:CardiopulmonarySegmentMember
2024-01-01
2024-09-30
0001639691
us-gaap:OperatingSegmentsMember
srt:EuropeMember
livn:CardiopulmonarySegmentMember
2025-07-01
2025-09-30
0001639691
us-gaap:OperatingSegmentsMember
srt:EuropeMember
livn:CardiopulmonarySegmentMember
2024-07-01
2024-09-30
0001639691
us-gaap:OperatingSegmentsMember
srt:EuropeMember
livn:CardiopulmonarySegmentMember
2025-01-01
2025-09-30
0001639691
us-gaap:OperatingSegmentsMember
srt:EuropeMember
livn:CardiopulmonarySegmentMember
2024-01-01
2024-09-30
0001639691
us-gaap:OperatingSegmentsMember
livn:LocationsExcludingTheUnitedStatesAndEuropeMember
livn:CardiopulmonarySegmentMember
2025-07-01
2025-09-30
0001639691
us-gaap:OperatingSegmentsMember
livn:LocationsExcludingTheUnitedStatesAndEuropeMember
livn:CardiopulmonarySegmentMember
2024-07-01
2024-09-30
0001639691
us-gaap:OperatingSegmentsMember
livn:LocationsExcludingTheUnitedStatesAndEuropeMember
livn:CardiopulmonarySegmentMember
2025-01-01
2025-09-30
0001639691
us-gaap:OperatingSegmentsMember
livn:LocationsExcludingTheUnitedStatesAndEuropeMember
livn:CardiopulmonarySegmentMember
2024-01-01
2024-09-30
0001639691
us-gaap:OperatingSegmentsMember
livn:CardiopulmonarySegmentMember
2025-07-01
2025-09-30
0001639691
us-gaap:OperatingSegmentsMember
livn:CardiopulmonarySegmentMember
2024-07-01
2024-09-30
0001639691
us-gaap:OperatingSegmentsMember
livn:CardiopulmonarySegmentMember
2025-01-01
2025-09-30
0001639691
us-gaap:OperatingSegmentsMember
livn:CardiopulmonarySegmentMember
2024-01-01
2024-09-30
0001639691
us-gaap:OperatingSegmentsMember
country:US
livn:NeuromodulationSegmentMember
2025-07-01
2025-09-30
0001639691
us-gaap:OperatingSegmentsMember
country:US
livn:NeuromodulationSegmentMember
2024-07-01
2024-09-30
0001639691
us-gaap:OperatingSegmentsMember
country:US
livn:NeuromodulationSegmentMember
2025-01-01
2025-09-30
0001639691
us-gaap:OperatingSegmentsMember
country:US
livn:NeuromodulationSegmentMember
2024-01-01
2024-09-30
0001639691
us-gaap:OperatingSegmentsMember
srt:EuropeMember
livn:NeuromodulationSegmentMember
2025-07-01
2025-09-30
0001639691
us-gaap:OperatingSegmentsMember
srt:EuropeMember
livn:NeuromodulationSegmentMember
2024-07-01
2024-09-30
0001639691
us-gaap:OperatingSegmentsMember
srt:EuropeMember
livn:NeuromodulationSegmentMember
2025-01-01
2025-09-30
0001639691
us-gaap:OperatingSegmentsMember
srt:EuropeMember
livn:NeuromodulationSegmentMember
2024-01-01
2024-09-30
0001639691
us-gaap:OperatingSegmentsMember
livn:LocationsExcludingTheUnitedStatesAndEuropeMember
livn:NeuromodulationSegmentMember
2025-07-01
2025-09-30
0001639691
us-gaap:OperatingSegmentsMember
livn:LocationsExcludingTheUnitedStatesAndEuropeMember
livn:NeuromodulationSegmentMember
2024-07-01
2024-09-30
0001639691
us-gaap:OperatingSegmentsMember
livn:LocationsExcludingTheUnitedStatesAndEuropeMember
livn:NeuromodulationSegmentMember
2025-01-01
2025-09-30
0001639691
us-gaap:OperatingSegmentsMember
livn:LocationsExcludingTheUnitedStatesAndEuropeMember
livn:NeuromodulationSegmentMember
2024-01-01
2024-09-30
0001639691
us-gaap:OperatingSegmentsMember
livn:NeuromodulationSegmentMember
2025-07-01
2025-09-30
0001639691
us-gaap:OperatingSegmentsMember
livn:NeuromodulationSegmentMember
2024-07-01
2024-09-30
0001639691
us-gaap:OperatingSegmentsMember
livn:NeuromodulationSegmentMember
2025-01-01
2025-09-30
0001639691
us-gaap:OperatingSegmentsMember
livn:NeuromodulationSegmentMember
2024-01-01
2024-09-30
0001639691
us-gaap:CorporateNonSegmentMember
2025-07-01
2025-09-30
0001639691
us-gaap:CorporateNonSegmentMember
2024-07-01
2024-09-30
0001639691
us-gaap:CorporateNonSegmentMember
2025-01-01
2025-09-30
0001639691
us-gaap:CorporateNonSegmentMember
2024-01-01
2024-09-30
0001639691
country:US
2025-07-01
2025-09-30
0001639691
country:US
2024-07-01
2024-09-30
0001639691
country:US
2025-01-01
2025-09-30
0001639691
country:US
2024-01-01
2024-09-30
0001639691
srt:EuropeMember
2025-07-01
2025-09-30
0001639691
srt:EuropeMember
2024-07-01
2024-09-30
0001639691
srt:EuropeMember
2025-01-01
2025-09-30
0001639691
srt:EuropeMember
2024-01-01
2024-09-30
0001639691
livn:LocationsExcludingTheUnitedStatesAndEuropeMember
2025-07-01
2025-09-30
0001639691
livn:LocationsExcludingTheUnitedStatesAndEuropeMember
2024-07-01
2024-09-30
0001639691
livn:LocationsExcludingTheUnitedStatesAndEuropeMember
2025-01-01
2025-09-30
0001639691
livn:LocationsExcludingTheUnitedStatesAndEuropeMember
2024-01-01
2024-09-30
0001639691
us-gaap:OperatingSegmentsMember
2025-07-01
2025-09-30
0001639691
us-gaap:OperatingSegmentsMember
2024-07-01
2024-09-30
0001639691
us-gaap:OperatingSegmentsMember
2025-01-01
2025-09-30
0001639691
us-gaap:OperatingSegmentsMember
2024-01-01
2024-09-30
0001639691
us-gaap:OperatingSegmentsMember
livn:CardiopulmonarySegmentMember
2025-09-30
0001639691
us-gaap:OperatingSegmentsMember
livn:CardiopulmonarySegmentMember
2024-12-31
0001639691
us-gaap:OperatingSegmentsMember
livn:NeuromodulationSegmentMember
2025-09-30
0001639691
us-gaap:OperatingSegmentsMember
livn:NeuromodulationSegmentMember
2024-12-31
0001639691
us-gaap:CorporateNonSegmentMember
2025-09-30
0001639691
us-gaap:CorporateNonSegmentMember
2024-12-31
0001639691
livn:CardiopulmonarySegmentMember
2024-12-31
0001639691
livn:NeuromodulationSegmentMember
2024-12-31
0001639691
livn:CardiopulmonarySegmentMember
2025-01-01
2025-09-30
0001639691
livn:NeuromodulationSegmentMember
2025-01-01
2025-09-30
0001639691
livn:CardiopulmonarySegmentMember
2025-09-30
0001639691
livn:NeuromodulationSegmentMember
2025-09-30
0001639691
country:US
2025-09-30
0001639691
country:US
2024-12-31
0001639691
srt:EuropeMember
2025-09-30
0001639691
srt:EuropeMember
2024-12-31
0001639691
livn:LocationsExcludingTheUnitedStatesAndEuropeMember
2025-09-30
0001639691
livn:LocationsExcludingTheUnitedStatesAndEuropeMember
2024-12-31
0001639691
livn:A2025NotesMember
us-gaap:EmbeddedDerivativeFinancialInstrumentsMember
2025-07-01
2025-09-30
0001639691
livn:A2025NotesMember
us-gaap:EmbeddedDerivativeFinancialInstrumentsMember
2024-07-01
2024-09-30
0001639691
livn:A2025NotesMember
us-gaap:EmbeddedDerivativeFinancialInstrumentsMember
2025-01-01
2025-09-30
0001639691
livn:A2025NotesMember
us-gaap:EmbeddedDerivativeFinancialInstrumentsMember
2024-01-01
2024-09-30
0001639691
livn:A2029NotesMember
us-gaap:EmbeddedDerivativeFinancialInstrumentsMember
2025-07-01
2025-09-30
0001639691
livn:A2029NotesMember
us-gaap:EmbeddedDerivativeFinancialInstrumentsMember
2024-07-01
2024-09-30
0001639691
livn:A2029NotesMember
us-gaap:EmbeddedDerivativeFinancialInstrumentsMember
2025-01-01
2025-09-30
0001639691
livn:A2029NotesMember
us-gaap:EmbeddedDerivativeFinancialInstrumentsMember
2024-01-01
2024-09-30
0001639691
livn:A2025NotesMember
livn:CappedCallMember
2025-07-01
2025-09-30
0001639691
livn:A2025NotesMember
livn:CappedCallMember
2024-07-01
2024-09-30
0001639691
livn:A2025NotesMember
livn:CappedCallMember
2025-01-01
2025-09-30
0001639691
livn:A2025NotesMember
livn:CappedCallMember
2024-01-01
2024-09-30
0001639691
livn:A2029NotesMember
livn:CappedCallMember
2025-07-01
2025-09-30
0001639691
livn:A2029NotesMember
livn:CappedCallMember
2024-07-01
2024-09-30
0001639691
livn:A2029NotesMember
livn:CappedCallMember
2025-01-01
2025-09-30
0001639691
livn:A2029NotesMember
livn:CappedCallMember
2024-01-01
2024-09-30
0001639691
livn:ShiraTronicsInc.Member
2024-01-01
2024-09-30
0001639691
livn:CeribellInc.Member
2025-04-01
2025-06-30
0001639691
livn:CeribellInc.Member
2025-06-30
0001639691
livn:CeribellInc.Member
2018-12-31
0001639691
us-gaap:JudicialRulingMember
livn:SNIAMember
us-gaap:BridgeLoanMember
2022-03-18
0001639691
srt:ScenarioPreviouslyReportedMember
2024-01-01
2024-12-31
0001639691
srt:RestatementAdjustmentMember
2024-01-01
2024-12-31
0001639691
srt:ScenarioPreviouslyReportedMember
2023-01-01
2023-12-31
0001639691
srt:RestatementAdjustmentMember
2023-01-01
2023-12-31
0001639691
2023-01-01
2023-12-31
0001639691
srt:ScenarioPreviouslyReportedMember
2025-01-01
2025-03-31
0001639691
srt:RestatementAdjustmentMember
2025-01-01
2025-03-31
0001639691
2025-01-01
2025-03-31
0001639691
srt:ScenarioPreviouslyReportedMember
2024-01-01
2024-03-31
0001639691
srt:RestatementAdjustmentMember
2024-01-01
2024-03-31
0001639691
2024-01-01
2024-03-31
0001639691
srt:ScenarioPreviouslyReportedMember
2024-07-01
2024-09-30
0001639691
srt:RestatementAdjustmentMember
2024-07-01
2024-09-30
0001639691
srt:ScenarioPreviouslyReportedMember
2024-01-01
2024-09-30
0001639691
srt:RestatementAdjustmentMember
2024-01-01
2024-09-30
0001639691
srt:ScenarioPreviouslyReportedMember
livn:CardiopulmonarySegmentMember
2024-01-01
2024-12-31
0001639691
srt:RestatementAdjustmentMember
livn:CardiopulmonarySegmentMember
2024-01-01
2024-12-31
0001639691
livn:CardiopulmonarySegmentMember
2024-01-01
2024-12-31
0001639691
srt:ScenarioPreviouslyReportedMember
livn:CardiopulmonarySegmentMember
2023-01-01
2023-12-31
0001639691
srt:RestatementAdjustmentMember
livn:CardiopulmonarySegmentMember
2023-01-01
2023-12-31
0001639691
livn:CardiopulmonarySegmentMember
2023-01-01
2023-12-31
0001639691
srt:ScenarioPreviouslyReportedMember
livn:CardiopulmonarySegmentMember
2025-01-01
2025-03-31
0001639691
srt:RestatementAdjustmentMember
livn:CardiopulmonarySegmentMember
2025-01-01
2025-03-31
0001639691
livn:CardiopulmonarySegmentMember
2025-01-01
2025-03-31
0001639691
srt:ScenarioPreviouslyReportedMember
livn:CardiopulmonarySegmentMember
2024-01-01
2024-03-31
0001639691
srt:RestatementAdjustmentMember
livn:CardiopulmonarySegmentMember
2024-01-01
2024-03-31
0001639691
livn:CardiopulmonarySegmentMember
2024-01-01
2024-03-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________________
Form 
10-Q

(Mark One)
☑

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended: 
September 30, 2025
or
☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _______________ to _______________
Commission file number: 
001-37599

LivaNova PLC
(Exact name of registrant as specified in its charter)
England and Wales

...................

98-1268150

(State or other jurisdiction of 
..........

(I.R.S. Employer
incorporation or organization) 
........

Identification No.)
20 Eastbourne Terrace
, 
London
, 
United Kingdom
, 
W2 6LG
(Address of principal executive offices) 
.......................

(Zip Code)
Registrant
’
s telephone number, including area code: 
(
44
) (
0
) 
203 325-0660

Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Ordinary Shares - £1.00 par value per share
LIVN
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. 
Yes

☑
 No 
☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). 
Yes

☑ 
No 
☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☑
Accelerated filer
☐
Non-accelerated filer
☐
Smaller reporting company
☐
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes 
☐
 No 
☑
Class
Outstanding on October 29, 2025
Ordinary Shares - £1.00 par value per share
54,605,527
LIVANOVA PLC
TABLE OF CONTENTS
Item
Description
Page
Definitions
1
Intellectual Property, Trademarks, and Trade Names
4
Cautionary Note About Forward-Looking Statements
5
PART I. FINANCIAL INFORMATION
1.
Financial Statements (unaudited)
6
2.
Management’s Discussion and Analysis of Financial Condition and Results of Operations
29
3.
Quantitative and Qualitative Disclosures About Market Risk
36
4.
Controls and Procedures
36

PART II. OTHER INFORMATION
1.
Legal Proceedings
37
1A.
Risk Factors
37
2.
Unregistered Sales of Equity Securities and Use of Proceeds
37
3.
Defaults Upon Senior Securities
37
4.
Mine Safety Disclosures
37
5.
Other Information
37
6.
Exhibits
38
Signatures
39
DEFINITIONS
In this Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, the following terms and abbreviations have the meanings listed below. “LivaNova” and the “Company” refer to LivaNova PLC and its consolidated subsidiaries. 
Abbreviation
Definition
2015 Plan
LivaNova PLC 2015 Incentive Award Plan
2016 Decision
Decision by the Court of Milan in 2016 to dismiss all legal actions of SNIA and of the Public Administrations and to further require the Public Administrations to pay Sorin €292,000 for legal fees
2021 First Lien Credit Agreement
First Lien Credit Agreement between LivaNova PLC and its wholly-owned subsidiary, LivaNova USA, Inc., and Goldman Sachs Bank USA, as First Lien Administrative Agent and First Lien Collateral Agent, entered into on August 13, 2021
2024 Form 10-K
LivaNova PLC’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on February 25, 2025
2024 Restructuring Plan
A plan, initiated during the first quarter of 2024, to enhance LivaNova’s focus on its core Cardiopulmonary and Neuromodulation segments
2025 Capped Calls
Privately-negotiated capped call transactions entered into with certain financial institutions
2025 Director Incentive Plan
LivaNova PLC 2025 Director Incentive Plan
2025 Notes
$287.5 million aggregate principal amount 3.00% unsecured cash exchangeable senior notes due December 15, 2025, by private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act, issued by LivaNova USA on June 17, 2020
2025 Notes Repurchase Transaction
Repurchase of $230.0 million aggregate principal amount of the 2025 Notes in privately-negotiated transactions from proceeds from the issuance of the 2029 Notes
2029 Capped Calls
Privately-negotiated capped call transactions entered into with certain financial institutions
2029 Notes
$345.0 million aggregate principal amount 2.50% unsecured convertible senior notes due 2029 by private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act, issued by LivaNova PLC on March 8, 2024
A&R 2022 Plan
Amended and Restated LivaNova PLC 2022 Incentive Award Plan
ACS
Advanced Circulatory Support
AHI
Apnea-hypopnea index
ALung
ALung Technologies, Inc.
AOCI
Accumulated other comprehensive income (loss)
ASU
Accounting Standards Update
Barclays
Barclays Bank Ireland PLC
Capped Call Transactions
The 2025 Capped Calls and the 2029 Capped Calls
CEO
Chief Executive Officer
CFO
Chief Financial Officer
CMS
The U.S. Centers for Medicare & Medicaid Services
CODM
Chief Operating Decision Maker
Court of Appeal
Court of Appeal in Milan
Delayed Draw Term Facility
$50.0 million delayed draw term facility under the 2021 First Lien Credit Agreement, resulting from the Incremental Facility Amendment No. 2
DRE
Drug-resistant epilepsy
DTD
Difficult-to-treat depression - The Company’s broader business and strategic communications reference DTD as the preferred disease state when speaking more broadly about depression treatment, as it is a more inclusive and clinically evolving concept that encompasses patients whose depression continues to cause significant burden despite usual treatment efforts. Meanwhile, LivaNova’s RECOVER clinical study defines the patient population using the inclusion criteria for TRD, typically characterized by major depressive disorder that does not adequately respond to at least two different antidepressant treatments given at an appropriate dose and duration. As a result, the Company uses TRD in the context of the RECOVER study to maintain consistency with the study protocol approved by the U.S. Centers for Medicare & Medicaid Services. References to either term in this filing are context-dependent but describe overlapping populations.
1
Abbreviation
Definition
EBT
LivaNova PLC Employee Benefit Trust
ECJ
European Court of Justice
Embedded Derivatives
The bifurcated embedded derivatives associated with the 2025 Notes and 2029 Notes, collectively
Exchange Act
U.S. Securities Exchange Act of 1934, as amended
FASB
Financial Accounting Standards Board
FX
Foreign currency exchange rate
HLM
Heart-lung machine
ImThera
ImThera Medical, Inc. was a company developing an implantable neurostimulation device system for the treatment of obstructive sleep apnea that LivaNova acquired in 2018
Incremental Facility Amendment No. 2
An incremental facility amendment to the 2021 First Lien Credit Agreement, dated July 6, 2022
Initial Term Facility
$300.0 million term facility under the 2021 First Lien Credit Agreement, resulting from the Incremental Facility Amendment No. 2
ISIN
National Inspectorate for Nuclear Safety and Radiation Protection, a sub-body of the Italian Ministry of Economic Development
LivaNova PLC
A public limited company organized under the laws of England and Wales on February 20, 2015
LivaNova USA
LivaNova USA, Inc.
LSM
LivaNova Site Management S.r.l.
MDL
Federal multi-district litigation in the U.S. District Court for the Middle District of Pennsylvania
MedTech
Medical technology
Ministry
Collectively, the Ministry of Ecological Transition, the Ministry of Economy and Finance, and the Prime Minister’s Office
Nasdaq
Nasdaq Global Select Market
OBBBA
One Big Beautiful Bill Act
ODI
Oxygen desaturation index
Option Counterparties
Certain financial institutions with whom LivaNova USA or LivaNova PLC, as applicable, has entered into the 2025 Capped Calls and 2029 Capped Calls
OSA
Obstructive sleep apnea
OSPREY clinical trial
LivaNova’s clinical trial, “Treating Obstructive Sleep Apnea using Targeted Hypoglossal Neurostimulation”
Public Administrations
The Italian Ministry of the Environment and other Italian government agencies
R&D
Research and development
Report
This Quarterly Report on Form 10-Q
RSUs
Restricted stock units
SARs
Stock appreciation rights
SEC
U.S. Securities and Exchange Commission
Second A&R 2022 Plan
Second Amended and Restated LivaNova PLC 2022 Incentive Award Plan
Securities Act
U.S. Securities Act of 1933, as amended
SG&A
Selling, general, and administrative expenses
SNIA
SNIA S.p.A.
SNIA Litigation Guarantee
A first demand bank guarantee of €270.0 million in connection with the SNIA environmental litigation
Sorin 
Sorin S.p.A.
Term Facilities
The Initial Term Facility, together with the Delayed Draw Term Facility
2
Abbreviation
Definition
TRD
Treatment-resistant depression - LivaNova’s RECOVER clinical study defines the patient population using the inclusion criteria for TRD, typically characterized by major depressive disorder that does not adequately respond to at least two different antidepressant treatments given at an appropriate dose and duration. As a result, the Company uses TRD in the context of the RECOVER study to maintain consistency with the study protocol approved by the U.S. Centers for Medicare and Medicaid Services. Meanwhile, the Company’s broader business and strategic communications reference DTD as the preferred disease state when speaking more broadly about depression treatment, as it is a more inclusive and clinically evolving concept that encompasses patients whose depression continues to cause significant burden despite usual treatment efforts. References to either term in this filing are context-dependent but describe overlapping populations.
U.S.
United States of America
U.S. GAAP
Generally Accepted Accounting Principles in the U.S.
UK
United Kingdom
USD
U.S. dollar
VNS Therapy
LivaNova Vagus Nerve Stimulation Therapy
3
INTELLECTUAL PROPERTY, TRADEMARKS, AND TRADE NAMES
This Report may contain references to LivaNova’s proprietary intellectual property, including, among others:
•
Trademarks for LivaNova’s Neuromodulation systems, the VNS Therapy
™
 System, and LivaNova’s proprietary pulse generator products: Model 102 (Pulse
™
), Model 102R (Pulse Duo
™
), Model 103 (Demipulse
™
), Model 104 (Demipulse Duo
™
), Model 106 (AspireSR
™
), Model 1000 (SenTiva
™
), Model 1000-D (SenTiva
™
 Duo), and Model 8103 (Symmetry
™
).
•
Trademarks for LivaNova’s Cardiopulmonary products and systems: Essenz
™
, S5
™
, S5 Pro
™
, B-Capta
™
, Inspire
™
, Heartlink
™
, XTRA
™
, 3T Heater-Cooler
™
, Connect
™
, and Revolution
™
.
•
Trademarks for LivaNova’s advanced circulatory support systems: TandemLife
™
, TandemHeart
™
, TandemLung
™
, ProtekDuo
™
, LifeSPARC
™
, ALung
™
, Hemolung
™
, Respiratory Dialysis
™
, and ActivMix
™
.
•
Trademarks for LivaNova’s obstructive sleep apnea system: ImThera
™
 and aura6000
™
.
These trademarks and trade names are the property of LivaNova or the property of LivaNova’s consolidated subsidiaries and are protected under applicable intellectual property laws. Solely for convenience, LivaNova’s trademarks and trade names referred to in this Report may appear without the 
™
 symbol, but such references are not intended to indicate in any way that the Company will not assert, to the fullest extent under applicable law, LivaNova’s rights to these trademarks and trade names.
4
CAUTIONARY NOTE ABOUT FORWARD-LOOKING STATEMENTS
Certain statements in this Report, other than statements of historical or current fact, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section 21E of the Exchange Act. These statements include, but are not limited to, LivaNova’s plans, objectives, strategies, financial performance and outlook, trends, the amount and timing of future cash distributions, prospects or future events, and involve known and unknown risks that are difficult to predict. As a result, the Company’s actual financial results, performance, achievements, or prospects may differ materially from those expressed or implied by these forward-looking statements. Generally, forward-looking statements can be identified by the use of words such as “may,” “could,” “seek,” “guidance,” “predict,” “potential,” “likely,” “believe,” “will,” “should,” “expect,” “anticipate,” “estimate,” “plan,” “intend,” “forecast,” “foresee,” or variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based on estimates and assumptions that, while considered reasonable by LivaNova and its management based on their knowledge and understanding of the business and industry, are inherently uncertain. These statements are not guarantees of future performance, and stockholders should not place undue reliance on forward-looking statements. There are a number of risks, uncertainties, and other important factors, many of which are beyond the Company’s control, that could cause the Company’s actual results to differ materially from the forward-looking statements contained in this Report, and include, but are not limited to, the following risks and uncertainties: volatility in the global market and worldwide economic conditions, including as caused by the invasion of Ukraine, the evolving instability in the Middle East, inflation, changing interest rates, foreign exchange fluctuations, and changes to existing trade agreements and relationships between the U.S. and other countries, including the implementation of tariffs, trade restrictions, and sanctions; adverse changes in export and import costs and other trade restrictions as well as uncertainty over global tariffs; risks relating to supply chain pressures; cybersecurity incidents or other disruptions to the Company’s information technology systems or those of third parties with which the Company interacts; costs of complying with privacy and security of personal information requirements and laws; changes in technology, including the development of superior or alternative technology or devices by competitors and/or competition from providers of alternative medical therapies; failure of R&D investments or investment collaborations to be successful; prolonged government shutdowns in the U.S. which may result in delays in FDA or CMS activities, including product approvals or reimbursement determinations; failure to maintain appropriate working relationships with healthcare professionals to aid in the continuing development of products; the risk of quality issues and the impacts thereof; risks relating to recalls, replacement of inventory, enforcement actions, or product liability claims; failure to comply with, or changes in, laws, regulations, or administrative practices affecting government regulation of the Company’s products; failure to retain key personnel, succession plan, and negotiate with local works councils; failure to obtain approvals or reimbursement in relation to the Company’s products; unfavorable results from clinical studies or failure to meet milestones; pending or existing climate change; global healthcare policy changes that may lead to restricted access and pricing as well as payback requirements and limited reimbursement; changes or reduction in reimbursement for the Company’s products or failure to comply with rules relating to reimbursement of healthcare goods and services; failure to comply with rules relating to healthcare goods and services as well as anti-bribery laws; product liability, intellectual property, shareholder-related, environmental-related, income tax, and other litigation, disputes, losses, and costs, including in the case of the Company’s 3T Heater-Cooler litigation; risks associated with environmental laws and regulations as well as environmental liabilities, violations, and litigation, including in the case of Saluggia and SNIA; failure to protect the Company’s proprietary intellectual property; risks relating to the Company’s indebtedness; failure of divestitures and/or new acquisitions to further the Company’s strategic objectives or strengthen the Company’s existing businesses; the potential for impairments of intangible assets, goodwill, and other long-lived assets; changes in tax laws and regulations, including exposure to additional income tax liabilities; effectiveness of the Company’s internal controls over financial reporting; changes in the Company’s profitability and/or failure to manage costs and expenses; fluctuations in future quarterly operating results and/or variations in revenue and operating expenses relative to estimates; and other unknown or unpredictable factors that could harm the Company’s financial performance.
Other factors that could cause LivaNova’s actual results to differ from projected results are described in: (1) “Part II, Item 1A. Risk Factors” and elsewhere in this Report and the Company’s other Quarterly Reports on Form 10-Q, (2) the Company’s 2024 Form 10-K, (3) the Company’s reports and registration statements filed with and furnished from time to time to the SEC, and (4) other announcements LivaNova makes from time to time.
Readers are cautioned not to place undue reliance on the Company’s forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to update or revise any forward-looking statements after the date they are made, whether as a result of new information, future events, or otherwise. The following discussion and analysis should be read in conjunction with the Company’s unaudited condensed consolidated financial statements and related notes included elsewhere in this Report. Operating results for the nine months ended September 30, 2025 are not necessarily indicative of future results, including the full fiscal year. Please also refer to the Company’s “Annual Consolidated Financial Statements,” “Notes” thereto, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and “Risk Factors” contained in LivaNova’s 2024 Form 10-K and in the Company’s Quarterly Reports on Form 10-Q.
Financial Information and Currency of Financial Statements
All of the financial information included in this Report has been prepared in accordance with U.S. GAAP. The reporting currency of the Company’s condensed consolidated financial statements is USD.
5
PART I. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
LIVANOVA PLC AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS)
(UNAUDITED)
(In thousands, except per share amounts)
Three Months Ended September 30,
Nine Months Ended September 30,
2025
2024
2025
2024
Net revenue
$
357,753

$
318,120

$
1,027,132

$
931,607

Cost of sales
112,898

97,091

327,035

292,492

Gross profit
244,855

221,029

700,097

639,115

Operating expenses:
Selling, general, and administrative
138,522

127,426

405,448

378,238

Research and development
48,577

48,805

133,641

139,206

Other operating expense
3,744

9,180

4,196

29,641

Operating income
54,012

35,618

156,812

92,030

SNIA environmental liability expense
(
1,745
)
—

(
363,815
)
—

Interest expense
(
10,863
)
(
15,878
)
(
38,429
)
(
47,303
)
Loss on debt extinguishment
—

—

(
2,651
)
(
25,482
)
Foreign exchange and other income/(expense)
(
7,493
)
24,701

(
332
)
12,585

Income (loss) before income tax
33,911

44,441

(
248,415
)
31,830

Income tax expense
7,114

11,525

24,921

24,469

(Loss) income from equity method investments
(
13
)
37

(
41
)
(
18
)
Net income (loss)
$
26,784

$
32,953

$
(
273,377
)
$
7,343

Basic income (loss) per share
$
0.49

$
0.61

$
(
5.01
)
$
0.14

Diluted income (loss) per share
$
0.49

$
0.60

$
(
5.01
)
$
0.13

Shares used in computing basic income (loss) per share
54,630

54,352

54,529

54,194

Shares used in computing diluted income (loss) per share
55,153

54,585

54,529

54,526

See accompanying notes to the condensed consolidated financial statements.
6
LIVANOVA PLC AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF

COMPREHENSIVE INCOME (LOSS) 
(UNAUDITED)
(In thousands)
Three Months Ended September 30,
Nine Months Ended September 30,
2025
2024
2025
2024
Net income (loss)
$
26,784

$
32,953

$
(
273,377
)
$
7,343

Other comprehensive (loss) income:
Foreign currency translation adjustment
(
2,605
)
26,116

85,678

1,180

Other comprehensive (loss) income, net of tax
(
2,605
)
26,116

85,678

1,180

Comprehensive income (loss)
$
24,179

$
59,069

$
(
187,699
)
$
8,523

See accompanying notes to the condensed consolidated financial statements.
7
LIVANOVA PLC AND SUBSIDIARIES
CONDENSED CONSOLIDATED

BALANCE SHEETS
(UNAUDITED)
(In thousands, except share amounts)

September 30, 2025
December 31, 2024
ASSETS
Current Assets:
Cash and cash equivalents
$
646,079

$
428,858

Restricted cash
—

294,698

Accounts receivable, net of allowance of $
13,313
 at September 30, 2025 and $
11,275
 at December 31, 2024
211,579

193,158

Inventories
167,538

147,566

Prepaid and refundable taxes
27,531

30,544

Prepaid expenses and other current assets
44,422

32,362

Total Current Assets
1,097,149

1,127,186

Property, plant, and equipment, net
218,510

170,260

Goodwill
791,034

750,006

Intangible assets, net
234,530

237,294

Operating lease assets
51,197

46,837

Investments
15,049

25,084

Deferred tax assets
107,305

111,855

Long-term derivative assets
28,011

23,735

Other assets
14,798

14,132

Total Assets
$
2,557,583

$
2,506,389

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities:
Current debt obligations
$
85,440

$
78,004

Accounts payable
88,156

69,726

Accrued liabilities and other
92,229

118,485

SNIA environmental liability
394,587

—

Current contingent consideration
49,041

—

Current litigation provision liability
16,499

12,918

Taxes payable
21,373

32,456

Accrued employee compensation and related benefits
80,263

80,536

Total Current Liabilities
827,588

392,125

Long-term debt obligations
349,031

549,624

Long-term contingent consideration
40,641

84,218

Deferred tax liabilities
10,096

10,915

Long-term operating lease liabilities
43,075

40,105

Long-term employee compensation and related benefits
13,543

12,847

Long-term derivative liabilities
64,515

51,819

Other long-term liabilities
51,864

44,478

Total Liabilities
1,400,353

1,186,131

Commitments and contingencies (Note 5)
Stockholders’ Equity:
Ordinary Shares, £
1.00
 par value: unlimited shares authorized; 
55,503,264
 shares issued and 
54,605,279
 shares outstanding at September 30, 2025; 
54,437,670
 shares issued and 
54,348,542
 shares outstanding at December 31, 2024
84,520

83,156

Additional paid-in capital
2,245,024

2,220,658

Accumulated other comprehensive income (loss)
5,508

(
80,170
)
Accumulated deficit
(
1,176,627
)
(
903,250
)
Treasury stock at cost, 
897,985
 ordinary shares at September 30, 2025; 
89,128
 ordinary shares at December 31, 2024
(
1,195
)
(
136
)
Total Stockholders’ Equity
1,157,230

1,320,258

Total Liabilities and Stockholders’ Equity
$
2,557,583

$
2,506,389

See accompanying notes to the condensed consolidated financial statements.
8
LIVANOVA PLC AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF

CASH FLOWS
(UNAUDITED)
(In thousands)
Nine Months Ended September 30,
2025
2024
Operating Activities:
Net (loss) income
$
(
273,377
)
$
7,343

Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Stock-based compensation
26,904

26,984

Depreciation
21,008

18,683

Amortization of debt issuance costs
17,259

15,692

Remeasurement of derivative instruments
(
16,990
)
400

Amortization of intangible assets
13,186

12,960

Amortization of operating lease assets
10,732

6,918

Remeasurement of contingent consideration to fair value
5,464

338

Deferred income tax expense
4,066

9,093

Loss on investment revaluation - Ceribell, Inc.
3,622

—

Loss on debt extinguishment
2,651

25,482

Impairments of investments
1,112

5,768

Other
2,427

1,453

Changes in operating assets and liabilities:
Accounts receivable, net
(
5,830
)
17,425

Inventories
(
8,100
)
(
13,895
)
Other current and non-current assets
50,582

(
14,841
)
Accounts payable and accrued current and non-current liabilities
(
36,051
)
(
23,383
)
Taxes payable
(
13,575
)
2,628

SNIA environmental liability
363,815

—

Litigation provision liability
3,038

5,283

Net cash provided by operating activities
171,943

104,331

Investing Activities:
Purchases of property, plant, and equipment
(
48,817
)
(
36,701
)
Proceeds from investments
6,522

—

Other
(
358
)
(
751
)
Net cash used in investing activities
(
42,653
)
(
37,452
)
Financing Activities:
Repayment of long-term debt obligations
(
216,813
)
(
243,174
)
Shares repurchased from employees for minimum tax withholding
(
3,625
)
(
8,071
)
Proceeds from long-term debt obligations
—

335,513

Payment of debt extinguishment costs
—

(
38,953
)
Purchase of capped calls
—

(
31,637
)
Proceeds from unwind of capped calls
—

22,523

Payment of contingent consideration
—

(
13,750
)
Payment of debt issuance costs
—

(
5,931
)
Proceeds from exercise of stock options
33

5,028

Other
(
2,371
)
447

Net cash (used in) provided by financing activities
(
222,776
)
21,995

Effect of exchange rate changes on cash, cash equivalents, and restricted cash
16,009

(
170
)
Net (decrease) increase in cash, cash equivalents, and restricted cash
(
77,477
)
88,704

Cash, cash equivalents, and restricted cash at beginning of period
723,556

577,872

Cash, cash equivalents, and restricted cash at end of period
$
646,079

$
666,576

Supplemental noncash investing and financing transaction:
Asset obtained in exchange for finance lease obligation
$
4,760

$
—

See accompanying notes to the condensed consolidated financial statements.
9
LIVANOVA PLC AND SUBSIDIARIES
NOTES

TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Note 1. Unaudited Condensed Consolidated Financial Statements 
Basis of Presentation 
The accompanying unaudited condensed consolidated financial statements of LivaNova and the notes thereto as of and for the three and nine months ended September 30, 2025 and 2024 have been prepared in accordance with U.S. GAAP for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. The accompanying condensed consolidated balance sheet of LivaNova as of December 31, 2024 has been derived from audited consolidated financial statements contained in LivaNova’s 2024 Form 10-K but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, the condensed consolidated financial statements reflect all adjustments considered necessary for a fair statement of the operating results of LivaNova and its subsidiaries for the three and nine months ended September 30, 2025, and are not necessarily indicative of the results that may be expected for the year ending December 31, 2025. The financial information presented herein should be read in conjunction with the audited consolidated financial statements and notes thereto accompanying LivaNova’s 2024 Form 10-K.
Cybersecurity Incident
As previously disclosed, in November 2023, LivaNova detected a cybersecurity incident that resulted in a disruption of portions of the Company’s information technology systems. As a result, the Company engaged external cybersecurity experts, coordinated with law enforcement, implemented remediation measures, and notified affected individuals and regulators as required by applicable law. The incident was contained, and the Company’s mitigation efforts are considered complete. For further discussion on legal and regulatory developments, refer to “Note 5. Commitments and Contingencies.” 
Through September 30, 2025, LivaNova incurred direct costs totaling $
13.1
 million in connection with this cybersecurity incident, including $
0.1
 million and $
2.5
 million for the three months ended September 30, 2025 and 2024, respectively, and $
1.5
 million and $
8.2
 million for the nine months ended September 30, 2025 and 2024, respectively. The total direct costs incurred primarily include external cybersecurity expert and legal fees, system restoration costs, and $
1.2
 million related to a class action settlement, and do not include business interruption losses. The Company may incur additional costs related to this incident in the future. LivaNova maintains insurance, including cyber insurance, which is subject to certain retentions and policy limitations that will likely limit the amount that the insurers may reimburse the Company. LivaNova has filed claims for insurance reimbursement of direct costs and business interruption losses related to this incident and has submitted additional claims and supplemental requests for reimbursement as new costs have been incurred. Through September 30, 2025, LivaNova has received $
9.6
 million, including $
6.2
 million in reimbursement of direct costs and $
3.4
 million in reimbursement of business interruption losses. For the nine months ended September 30, 2025, LivaNova received $
1.2
 million in reimbursement of direct costs. The Company’s insurance coverage may be insufficient to cover all costs and expenses related to this cybersecurity incident or may be unavailable to cover all costs and expenses related to this cybersecurity incident.
Revision of Previously Issued Financial Statements
During the second quarter of 2025, the Company identified and corrected an immaterial error related to the classification of certain employee costs in the Cardiopulmonary segment between cost of sales and selling, general, and administrative expense in the consolidated statements of income (loss). This misclassification understated cost of sales and overstated selling, general, and administrative expense by equal and offsetting amounts, with no impact to operating income (loss) or net income (loss) for annual and interim periods for the years ended December 31, 2023 and 2024 and the three months ended March 31, 2025. The Company evaluated the error and determined that the related impact was not material to the consolidated statements of income for any prior period and had no impact on the consolidated balance sheets, statements of comprehensive income (loss), statements of cash flows, or statements of stockholders’ equity for any of the above periods. The Company has revised the previously issued condensed consolidated statements of income (loss) for the three and nine months ended September 30, 2024 to correct for the error, and these revisions are reflected in this Form 10-Q. The Company will also correct previously reported financial information for this error in its future filings, as applicable. A summary of the corrections to the impacted financial statement line items in the previously issued consolidated statements of income (loss) and disaggregated Cardiopulmonary segment income disclosure for each affected period is presented in “Note 13. Revision of Previously Issued Financial Statements.”
10
Significant Accounting Policies
LivaNova’s significant accounting policies are included within “Note 2. Basis of Presentation, Use of Accounting Estimates, and Significant Accounting Policies” and “Note 3. Revenue Recognition” of LivaNova’s 2024 Form 10-K.
Note 2. Derivatives and Risk Management
Due to the global nature of LivaNova’s operations, the Company is exposed to FX fluctuations. LivaNova enters into FX derivative contracts to reduce the impact of FX fluctuations on earnings and cash flow.
LivaNova is also exposed to equity price risk in connection with its 2025 Notes and 2029 Notes, including exchange/conversion and settlement provisions based on the price of its ordinary shares at exchange/conversion or maturity of the 2025 Notes and 2029 Notes. The Capped Call Transactions associated with the 2025 Notes and 2029 Notes also include settlement provisions that are based on the price of LivaNova’s ordinary shares, subject to a capped price per share. LivaNova does not enter into derivative contracts for speculative purposes.
LivaNova measures all outstanding derivatives each period-end at fair value and reports the fair value as either financial assets or liabilities on the condensed consolidated balance sheets. At the inception of the contract, the derivative is designated as either a freestanding derivative or a hedge. Derivatives that are not designated as hedging instruments are referred to as freestanding derivatives, with changes in fair value included in earnings. These derivatives are intended to serve as economic hedges and follow the cash flows of the economic hedged item. The cash flows from these derivative contracts are reported as operating activities in LivaNova’s condensed consolidated statements of cash flows. LivaNova had no designated hedging instruments as of September 30, 2025 and December 31, 2024.
Freestanding FX Derivatives 
The gross notional amount of freestanding FX derivative contracts outstanding as of September 30, 2025 and December 31, 2024 was $
96.8
 million and $
442.3
 million, respectively. These derivative contracts are designed to offset the FX effects in earnings of various intercompany loans and trade receivables. LivaNova recorded net losses of $
0.2
 million and $
5.0
 million for the three months ended September 30, 2025 and 2024, respectively, and net gains of $
25.2
 million and net losses of $
0.1
 million for the nine months ended September 30, 2025 and 2024, respectively, from freestanding derivatives. These amounts are included in foreign exchange and other income/(expense) in LivaNova’s condensed consolidated statements of income (loss).
Capped Call Derivatives
The Capped Call Transactions are carried on the condensed consolidated balance sheets as a derivative asset at their estimated fair value and are adjusted at the end of each reporting period, with unrealized gain or loss reflected in foreign exchange and other income/(expense) in the condensed consolidated statements of income (loss). For additional information, refer to “Note 11. Supplemental Financial Information.” The Capped Call Transactions are measured at fair value using the Black-Scholes model utilizing observable and unobservable market data, including stock price, remaining contractual term, expected volatility, risk-free interest rate, and expected dividend yield, as applicable. For additional information regarding the Capped Call Transactions, refer to LivaNova’s 2024 Form 10-K.
Embedded Derivatives
The 2025 Notes and 2029 Notes each include terms resulting in a bifurcated embedded derivative. The Embedded Derivatives are measured at fair value using a binomial lattice model and estimated discounted cash flows that utilize observable and unobservable market data and are adjusted at the end of each reporting period, with the unrealized gain or loss reflected in foreign exchange and other income/(expense) in the condensed consolidated statements of income (loss). For additional information, refer to “Note 11. Supplemental Financial Information.”
Counterparty Credit Risk
LivaNova is exposed to credit risk in the event of non-performance by the counterparties to the Company’s derivatives.
The Option Counterparties are financial institutions. To limit LivaNova’s credit risk, the Company selected financial institutions with a minimum long-term investment grade credit rating. LivaNova’s exposure to the credit risk of the Option Counterparties is not secured by any collateral. If one or more of the Option Counterparties becomes subject to insolvency proceedings, LivaNova will become an unsecured creditor in those proceedings, with a claim equal to the Company’s exposure at that time under the 2025 Capped Calls and/or 2029 Capped Calls, as applicable, with that Option Counterparty.
11
To manage credit risk with respect to LivaNova’s FX derivatives, the Company selects and periodically reviews counterparties based on credit ratings, limits its exposure with respect to each counterparty, and monitors their respective market positions. However, if one or more of these counterparties were in a liability position to the Company and were unable to meet their obligations, any transactions with the counterparty could be subject to early termination, which could result in losses for the Company.
Balance Sheet Presentation
LivaNova offsets fair value amounts associated with its derivative instruments that are executed with the same counterparty under master netting arrangements on the Company’s condensed consolidated balance sheets. Master netting arrangements include a right to set off or net together purchases and sales of similar products in the settlement process.
The following tables present the fair value and the location of derivative contracts reported on the condensed consolidated balance sheets (in thousands):
Derivative Assets
Derivative Liabilities
September 30, 2025
Balance Sheet Location
Fair Value 
(1)
Balance Sheet Location
Fair Value 
(1)
Derivatives Not Designated as Hedging Instruments:
Capped call derivatives (2025 Notes)
Prepaid expenses and other current assets
$
1,627

Capped call derivatives (2029 Notes)
Long-term derivative assets
28,011

Embedded derivative (2025 Notes)
Accrued liabilities and other
$
1,685

Embedded derivative (2029 Notes)
Long-term derivative liabilities
64,515

FX derivative contracts
Accrued liabilities and other
203

Total derivatives not designated as hedging instruments
$
29,638

$
66,403

(1)
For the classification of inputs used to evaluate the fair value of LivaNova’s derivatives, refer to “Note 3. Fair Value Measurements.”
Derivative Assets
Derivative Liabilities
December 31, 2024
Balance Sheet Location
Fair Value 
(1)
Balance Sheet Location
Fair Value 
(1)
Derivatives Not Designated as Hedging Instruments:
Capped call derivatives (2025 Notes)
Prepaid expenses and other current assets
$
2,624

Capped call derivatives (2029 Notes)
Long-term derivative assets
23,735

Embedded derivative (2025 Notes)
Accrued liabilities and other
$
2,915

Embedded derivative (2029 Notes)
Long-term derivative liabilities
51,819

FX derivative contracts
Prepaid expenses and other current assets
738

Total derivatives not designated as hedging instruments
$
27,097

$
54,734

(1)
For the classification of inputs used to evaluate the fair value of LivaNova’s derivatives, refer to “Note 3. Fair Value Measurements.”
Note 3. Fair Value Measurements 
LivaNova reviews its fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities in the fair value hierarchy. There were no transfers between Level 1, Level 2, or Level 3 for the three and nine months ended September 30, 2025 and 2024.
12
Assets and Liabilities Measured at Fair Value on a Recurring Basis
The following tables present the level in the fair value hierarchy at which the Company’s assets and liabilities are measured on a recurring basis (in thousands):
Balance Sheet Location
September 30, 2025
Fair Value Measurements Using Inputs Considered as:
Level 1
Level 2
Level 3
Assets:
Derivative assets - capped call derivatives (2025 Notes)
Prepaid expenses and other current assets
$
1,627

$
—

$
—

$
1,627

Derivative assets - capped call derivatives (2029 Notes)
Long-term derivative assets
28,011

—

—

28,011

$
29,638

$
—

$
—

$
29,638

Liabilities:
Derivative liabilities - freestanding instruments (FX) 
Accrued liabilities and other
$
203

$
—

$
203

$
—

Derivative liabilities - embedded derivative (2025 Notes)
Accrued liabilities and other
1,685

—

—

1,685

Derivative liabilities - embedded derivative (2029 Notes)
Long-term derivative liabilities
64,515

—

—

64,515

ImThera contingent consideration arrangement
Current contingent consideration
49,041

—

—

49,041

ImThera contingent consideration arrangement
Long-term contingent consideration
40,641

—

—

40,641

$
156,085

$
—

$
203

$
155,882

Balance Sheet Location
December 31, 2024
Fair

Value Measurements Using Inputs Considered as:
Level 1
Level 2
Level 3
Assets
Derivative assets - freestanding instruments (FX)
Prepaid expenses and other current assets
$
738

$
—

$
738

$
—

Derivative assets - capped call derivatives (2025 Notes)
Prepaid expenses and other current assets
2,624

—

—

2,624

Derivative assets - capped call derivatives (2029 Notes)
Long-term derivative assets
23,735

—

—

23,735

Investment with readily determinable fair value
Investments
10,144

10,144

—

—

$
37,241

$
10,144

$
738

$
26,359

Liabilities
Derivative liabilities - embedded derivative (2025 Notes)
Accrued liabilities and other
$
2,915

$
—

$
—

$
2,915

Derivative liabilities - embedded derivative (2029 Notes)
Long-term derivative liabilities
51,819

—

—

51,819

ImThera contingent consideration arrangement
Long-term contingent consideration
84,218

—

—

84,218

$
138,952

$
—

$
—

$
138,952

13
Reconciliation of Level 3 Assets and Liabilities
The tables below present reconciliations of recurring fair value measurements that use significant unobservable inputs (Level 3) as of and for the three and nine months ended September 30, 2025 and 2024 (in thousands):
Capped Call Derivative Assets 
(2025 Notes)
Capped Call Derivative Assets 
(2029 Notes)
Embedded Derivative Liability 
(2025 Notes)
Embedded Derivative Liability 
(2029 Notes)
ImThera Contingent Consideration Liability 
June 30, 2025
$
1,303

$
21,658

$
1,363

$
48,093

$
87,927

Changes in fair value
324

6,353

322

16,422

1,755

September 30, 2025
$
1,627

$
28,011

$
1,685

$
64,515

$
89,682

Capped Call Derivative Assets 
(2025 Notes)
Capped Call Derivative Assets 
(2029 Notes)
Convertible Notes Receivable
Embedded Derivative Liability 
(2025 Notes)
Embedded Derivative Liability 
(2029 Notes)
Contingent Consideration Liability
June 30, 2024
$
7,439

$
32,114

$
275

$
10,017

$
95,392

$
81,174

Changes in fair value
(
1,668
)
(
2,517
)
(
275
)
(
2,829
)
(
18,423
)
66

September 30, 2024
$
5,771

$
29,597

$
—

$
7,188

$
76,969

$
81,240

Capped Call Derivative Assets 
(2025 Notes)
Capped Call Derivative Assets 
(2029 Notes)
Embedded Derivative Liability 
(2025 Notes)
Embedded Derivative Liability 
(2029 Notes)
ImThera Contingent Consideration Liability
December 31, 2024
$
2,624

$
23,735

$
2,915

$
51,819

$
84,218

Changes in fair value
(
997
)
4,276

(
1,230
)
12,696

5,464

September 30, 2025
$
1,627

$
28,011

$
1,685

$
64,515

$
89,682

Capped Call Derivative Assets 
(2025 Notes)
Capped Call Derivative Assets 
(2029 Notes)
Convertible Notes Receivable
Embedded Derivative Liability 
(2025 Notes)
Embedded Derivative Liability 
(2029 Notes)
Contingent Consideration Liability Arrangements
December 31, 2023
$
38,496

$
—

$
275

$
45,569

$
—

$
94,652

Additions
—

31,637

—

—

87,457

—

Cash receipt
(
22,524
)
—

—

—

—

—

Payment
—

—

—

(
36,915
)
—

(
13,750
)
Changes in fair value
(
10,201
)
(
2,040
)
(
275
)
(
1,466
)
(
10,488
)
338

September 30, 2024
$
5,771

$
29,597

$
—

$
7,188

$
76,969

$
81,240

Stock Price Volatility
The following table presents the stock price volatility utilized in determining the fair value of LivaNova’s capped call derivative assets and embedded derivative liabilities:
Stock Price Volatility
 (1)
Capped Call Derivative Assets 
(2025 Notes)
Capped Call Derivative Assets 
(2029 Notes)
Embedded Derivative Liability 
(2025 Notes)
Embedded Derivative Liability 
(2029 Notes)
September 30, 2025
46

%
39

%
46

%
39

%
December 31, 2024
37

%
35

%
37

%
35

%
(1)
    The embedded and capped call derivatives are classified as Level 3 because the Company uses historical volatility and implied volatility from actual options traded to determine expected stock price volatility, an unobservable input that is significant to the valuation. In general, an increase in LivaNova’s stock price or stock price volatility would increase the fair value of the embedded and capped call derivatives, which would result in an increase in net expense. As the remaining time to the expiration of the derivatives decreases, the fair value of the derivatives decreases. The future impact of the derivatives on net income (loss) depends 
14
on how significant inputs, such as stock price, stock price volatility, and time to the expiration of the derivatives, change in relation to other inputs.
Contingent Consideration Arrangements
The ImThera business combination involved contingent consideration arrangements comprised of potential cash payments upon the achievement of a certain regulatory milestone and a sales-based earnout associated with sales of products. The sales-based earnouts are valued using projected sales from LivaNova’s internal strategic plan. 
These arrangements are Level 3 fair value measurements and include the following significant unobservable inputs as of September 30, 2025:
ImThera Acquisition
Valuation Technique
Unobservable Input
Inputs
Regulatory milestone-based payment
Discounted cash flow
Discount rate
6.3
%
Probability of payment
85
%
Projected payment year
2026
Sales-based earnout
Monte-Carlo simulation
Risk-adjusted discount rate
13.0
% - 
13.1
%
Credit risk discount rate
6.5
% - 
7.0
%
Revenue volatility
23.3
%
Probability of payment
85
%
Projected years of earnout
2027 - 2030
Note 4. Financing Arrangements 
The following table presents a summary of LivaNova’s long-term debt obligations (in thousands, except interest rates):
September 30, 2025
December 31, 2024
Maturity
Interest Rate
Term Facilities
$
101,403

$
313,014

July 2027
7.38
%
2029 Notes
270,994

258,043

March 2029
2.50
%
2025 Notes
56,683

53,887

December 2025
3.00
%
Bank of America, U.S.
—

1,500

Other
5,374

519

Total long-term facilities
434,454

626,963

Less: Current portion of long-term debt
85,423

77,339

Total long-term debt obligations
$
349,031

$
549,624

Revolving Credit and Term Facilities
The outstanding principal amount of LivaNova’s short-term unsecured revolving credit agreements and other agreements with various banks was $
17
 thousand and $
0.7
 million at September 30, 2025 and December 31, 2024, respectively.
There were 
no
 outstanding borrowings under the $
225.0
 million revolving facilities under the 2021 First Lien Credit Agreement as of September 30, 2025 and December 31, 2024. As of September 30, 2025 and December 31, 2024, the applicable commitment fee percentage was 
0.25
% per annum and 
0.5
% per annum, respectively. As of September 30, 2025, the Company was in compliance with the financial covenants contained in the 2021 First Lien Credit Agreement.
Debt discount and issuance costs related to the Initial Term Facility were $
9.6
 million. The unamortized debt discount and issuance costs related to the Initial Term Facility were $
1.1
 million and $
4.8
 million as of September 30, 2025 and December 31, 2024, respectively. 
On May 2, 2025, LivaNova made an early repayment of $
200
 million on principal borrowings under the Term Facilities. The early repayment resulted in the recognition of a loss on debt extinguishment of $
2.7
 million for the nine months ended September 30, 2025, associated with the write-off of unamortized debt issuance costs, and is included within loss on debt extinguishment on the condensed consolidated statements of income (loss).
2029 Notes
The effective interest rate of the 2029 Notes was 
9.84
% as of September 30, 2025. The unamortized debt discount and issuance costs related to the 2029 Notes as of September 30, 2025 and December 31, 2024 were $
74.0
 million and $
87.0
 million, 
15
respectively. As of September 30, 2025, the conditions for conversion were not met. The Company included its obligations from the 2029 Notes and the associated embedded derivative as long-term liabilities on the condensed consolidated balance sheet as of September 30, 2025, and the 2029 Notes are not convertible for the three months ended December 31, 2025. For additional information regarding the 2029 Notes, refer to LivaNova’s 2024 Form 10-K.
2025 Notes
The effective interest rate of the 2025 Notes was 
9.92
% as of September 30, 2025. The unamortized debt discount and issuance costs related to the 2025 Notes as of September 30, 2025 and December 31, 2024 were $
0.8
 million and $
3.6
 million, respectively. Beginning on September 15, 2025, the 2025 Notes became exchangeable at the holder’s option, without any additional conditions, and remain exchangeable through the second scheduled trading day immediately preceding the maturity date of the 2025 Notes. The Company included its obligations from the 2025 Notes and the associated embedded derivative as current liabilities on the condensed consolidated balance sheet as of September 30, 2025. As of September 30, 2025, LivaNova held $
57.5
 million in cash designated for the December 2025 repayment of the 2025 Notes principal amount in a LivaNova-controlled depository account, which is included within cash and cash equivalents on the condensed consolidated balance sheet. For additional information regarding the 2025 Notes, refer to LivaNova’s 2024 Form 10-K.
Note 5. Commitments and Contingencies 
Saluggia Site Hazardous Substances
LSM, formerly a subsidiary of Sorin, one of the companies that merged into LivaNova PLC in 2015, manages site services for the campus in Saluggia, Italy. In addition to being a former LivaNova manufacturing facility, the Saluggia campus is also the location of manufacturing facilities of third parties, a cafeteria for workers, and storage facilities for hazardous substances and equipment previously used in a nuclear research center, later turned nuclear medicine business, between the 1960s and the late 1990s. Pursuant to authorization from the Italian government, LSM performs ordinary maintenance, secures the facilities, monitors air and water quality, and files applicable reports with the competent environmental authorities. 
In 2020, LSM received correspondence from ISIN requesting that, within 
five years
, LSM demonstrate the financial capacity to meet its obligations under Italian law to clean and dismantle any contaminated buildings and equipment, as well as to deliver hazardous substances to a national repository. The national repository will be built by the Italian government at a location and time yet to be determined. ISIN subsequently published Technical Guide n. 30, which identifies the technical criteria and general safety and protection requirements for the design, construction, operation, and dismantling of temporary storage facilities for the hazardous substances.
Although there is no legal obligation to deliver any hazardous substances, as the performance of these obligations is contingent on the construction of the as-yet unbuilt national repository, based on the aforementioned factors, the Company concluded its obligation to clean, dismantle, and deliver any hazardous substances to a national repository is probable and reasonably estimable. The estimated liability as of September 30, 2025 was $
40.3
 million (€
34.3
 million), which represented the estimated low end of the range of loss, with an estimated maximum end of the range of loss of $
55.2
 million (€
47.0
 million). The estimated liability as of December 31, 2024 was $
36.7
 million (€
35.4
 million). 
SNIA Environmental Litigation
Sorin was created as a result of a spin-off from SNIA in 2004. SNIA subsequently became insolvent, and the Public Administrations sought compensation from SNIA in an aggregate amount of approximately $
4.0
 billion for remediation costs relating to the environmental damage at chemical sites previously operated by SNIA’s other subsidiaries. Thereafter, in 2015, Sorin was merged into LivaNova.
There are proceedings relating to the SNIA bankruptcy to which LivaNova is not a party in the Bankruptcy Court of Udine and the Bankruptcy Court of Milan. In 2011, the Bankruptcy Court of Udine held that the Public Administrations were not creditors of either SNIA or its subsidiaries in connection with their claims in the Italian insolvency proceedings. The Public Administrations appealed. In 2016, the Court of Udine rejected the appeal, and the Public Administrations appealed to the Italian Supreme Court. Similarly, in 2014, the Bankruptcy Court of Milan held that the Public Administrations were not creditors of either SNIA or its subsidiaries. The Public Administrations appealed. In April 2022, the Bankruptcy Court of Milan declared the Public Administrations to be a non-privileged creditor of SNIA for up to €
453.6
 million ($
532.2
 million as of September 30, 2025), and the Public Administrations appealed to the Italian Supreme Court.
In 2012, SNIA filed a civil action against Sorin in the Civil Court of Milan, asserting joint liability of a parent and a spun-off company; the Public Administrations entered voluntarily into the proceeding, asking Sorin, as jointly liable with SNIA, to pay compensation for SNIA’s environmental damages. In 2016, the Court of Milan dismissed all legal actions of SNIA and of the Public Administrations, further requiring the Public Administrations to pay Sorin €
292,000
 ($
342,602
 as of September 30, 
16
2025) for legal fees. The Public Administrations appealed the 2016 Decision to the Court of Appeal. On March 5, 2019, the Court of Appeal issued a partial decision on the merits declaring Sorin/LivaNova jointly liable with SNIA for SNIA’s environmental liabilities in an amount up to the fair value of the net worth received by Sorin because of the spin-off of Sorin from SNIA in 2004, an estimated €
572.1
 million ($
671.2
 million as of September 30, 2025). LivaNova appealed the partial decision on liability to the Italian Supreme Court in August 2019.
In 2021, the Court of Appeal delivered the remainder of its decision, ordering LivaNova to pay damages of €
453.6
 million ($
532.2
 million as of September 30, 2025). LivaNova appealed the decision on damages in December 2021. On February 21, 2022, the Court of Appeal notified the Company that it granted the Company a suspension with respect to the payment of damages until a decision was reached on the appeal to the Italian Supreme Court. This suspension was subject to LivaNova providing a first demand bank guarantee of €
270.0
 million ($
316.8
 million as of September 30, 2025) within 
30
 calendar days, and on March 21, 2022, LivaNova delivered the SNIA Litigation Guarantee, thereby satisfying the condition. 
In 2022, in response to one of a number of appeals asserted by LivaNova, the Italian Supreme Court issued an ordinance, a procedural document, whereby the Italian Supreme Court referred a question on the interpretation of a European directive on demergers to the ECJ. Specifically, the ordinance asked the ECJ to provide a binding decision as to whether a company resulting from a demerger can be held jointly and severally liable not only for the established liabilities of the demerged company that were articulated at the time of demerger, but also for the environmental liabilities of the demerged company that materialized after the demerger which are derived from actions performed prior to the demerger. On July 29, 2024, the ECJ issued a judgment in response to the ordinance. The ECJ judgment states that a demerged company can be held responsible for liabilities not established prior to a demerger as long as the liabilities derive from the conduct of a demerged company prior to the demerger. The ECJ judgment also states that national law should determine whether liability for damages stemming from conduct after a demerger can be assigned to a demerged company. 
On March 14, 2025, the Italian Supreme Court issued its decision in response to all of the appeals of the Company and counter-appeals submitted by the Public Administrations. The Italian Supreme Court determined that LivaNova can be held jointly and severally liable for the established liabilities of SNIA at the time of demerger, as well as the environmental liabilities of the demerged company that materialized after the demerger, which are derived from actions performed prior to the demerger; however, the Italian Supreme Court also ruled that the Company should not be held responsible for certain payments previously approved by the Court of Appeal in the amount of €
157.3
 million ($
184.5
 million as of September 30, 2025). The case has been referred back to the Court of Appeal to implement the decisions respecting costs and damages in accordance with the judgment of the Italian Supreme Court. 
As a result of the decision by the Italian Supreme Court, the Company recorded a current liability in the first quarter of 2025 and has continued to accrue interest on the liability since that time. As of September 30, 2025, the Company has a current liability of €
336.3
 million ($
394.6
 million) on the condensed consolidated balance sheet, representing its best estimate of the liability, inclusive of estimated costs, fees, interest, and taxes. These estimated costs do not include the Company’s legal fees, which are expensed as incurred and included in SG&A in LivaNova’s condensed consolidated statements of income (loss). The Company has determined that it has sufficient resources to cover the liability as of September 30, 2025. 
On March 31, 2025, as a result of the decision by the Italian Supreme Court, the SNIA Litigation Guarantee was terminated, and the restriction on the cash deposit held as collateral was released. For additional information on the financing of the guarantee, refer to “Note 11. Supplemental Financial Information.”
On May 15, 2025, as a procedural step outlined above, the Ministry served the Company with a filing to return the proceedings to the Court of Appeal. In addition to seeking a return of the case to the Court of Appeal, the Ministry asserted that the Court of Appeal forgo an examination of the amounts disapproved by the Italian Supreme Court and instead impose costs of €
108.8
 million ($
127.7
 million as of September 30, 2025) at a minimum. These assertions are counter to the decision of the Italian Supreme Court’s judgment, which disapproved costs of €
157.3
 million ($
184.5
 million as of September 30, 2025). The Ministry’s filing is not a legal judgment or demand for payment. The Company disagrees with the assertions made in the Ministry’s filing and believes they contradict the decisions of the Italian Supreme Court. The Company intends to challenge the Ministry’s assertions and purported costs and to defend its position in accordance with the Italian Supreme Court’s judgment. The Company continues to believe that its recorded liability remains the best estimate of the liability associated with the SNIA matter, and, as such, no adjustments were made to the accrual in response to the filing on May 15, 2025. A hearing has been scheduled for January 28, 2026. 
Product Liability Litigation
The Company continues to be involved in litigation involving LivaNova’s 3T device. The litigation includes the cases remaining in the MDL and various U.S. state courts, as well as claims in jurisdictions outside the United States. As of 
17
November 5, 2025, the Company was aware of approximately 
65
 filed and unfiled claims worldwide. The complaints generally seek damages and other relief based on theories of strict liability, negligence, breach of express and implied warranties, failure to warn, design and manufacturing defect, fraudulent and negligent misrepresentation or concealment, unjust enrichment, and violations of various state consumer protection statutes.
For the three and nine months ended September 30, 2025, LivaNova recorded an additional liability of $
4.4
 million and $
5.0
 million, respectively, upon receiving new information regarding the nature of certain claims. As of September 30, 2025 and December 31, 2024, the provision for these matters was $
19.8
 million and $
15.8
 million, respectively. While the amount accrued represents LivaNova’s best estimate for those worldwide filed and unfiled claims of which LivaNova is aware and believes are both probable and estimable at this time, the actual liability for resolution of these matters may vary from the Company’s provision. A provision has not been recorded for any claims where a potential loss is not determined to be probable, or a potential loss or range of potential loss is not reasonably estimable at this time.
The following table presents the changes in the litigation provision liability for the nine months ended September 30, 2025 (in thousands):
As of December 31, 2024
$
15,843

Payments
(
1,951
)
Adjustments 
(1)
4,989

FX and other
895

As of September 30, 2025
19,776

Less: Current portion as of September 30, 2025
16,499

Long-term portion as of September 30, 2025 
(2)
$
3,277

(1)
Adjustments to the litigation provision are included in other operating expense on the condensed consolidated statements of income (loss).
(2)
Included in other long-term liabilities on the condensed consolidated balance sheets.
Italian MedTech Payback Measure
In 2015, the Italian Parliament introduced a law regarding public contracts with the National Healthcare System for the supply of goods and services. In particular, the law introduced a payback measure requiring companies selling medical devices in Italy to repay a percentage of the healthcare expenditures exceeding the regional maximum caps for medical devices. In August 2022, a decree was published that provided guidance and timetables for the payback measure. In response, LivaNova filed an appeal at the Administrative Court against the decree of the Ministry of Health, assessing the amount payable and against the payback law. LivaNova also filed appeals against the regions requesting payments. In July 2024, the Constitutional Court determined that the payback law is compliant with the Italian Constitution. Furthermore, on June 30, 2025, the Italian Government introduced a decree that would allow companies to settle their 2015-2018 payment obligations by paying 25% of the originally requested amounts if those companies were to withdraw any outstanding appeals related to that period and remit payment within 30 days of the law entering into force. The Italian Parliament subsequently converted the decree into law, and it entered into force on August 10, 2025. In September 2025, the Company paid €
3.5
 million ($
4.1
 million as of September 30, 2025), representing 25% of the originally requested amounts in full settlement of its 2015-2018 payment obligations and reversed the remaining $
3.8
 million reserve for that period. The related pending appeals are in the process of being withdrawn. As of September 30, 2025, the Company had a reserve of $
12.3
 million for the years 2019 to the present reflecting its best estimate of the full potential obligation; however, the actual liability could vary. As of December 31, 2024, the reserve was $
16.0
 million, including $
7.0
 million for the years 2015-2018. The reserve is included in accrued liabilities and other in the condensed consolidated balance sheets. Amounts recognized associated with the Italian MedTech payback measure are recorded as a reduction to net revenue in the condensed consolidated statements of income (loss).
Cyber Litigation
In connection with the cybersecurity incident initially reported on November 20, 2023, LivaNova USA was named as a defendant in 
six
 putative class action lawsuits filed in the United States District Court for the Southern District of Texas in June and July 2024. Those cases were consolidated in a single action, and the plaintiffs filed against LivaNova USA a consolidated class action complaint, which asserted claims of negligence, breach of contract, and violation of various state consumer protection laws. The plaintiffs sought damages, equitable/injunctive relief, and attorneys’ fees, costs, and expenses, among other relief. The parties entered into mediation and agreed to a class action settlement, with respect to which the Company recorded an accrual of $
1.2
 million for the quarter ended September 30, 2024. The class action settlement received approval from the court on April 4, 2025. The Company expects all settlement administration activities to be completed in 2025.
18
In addition, HHS’s Office for Civil Rights is investigating the incident pursuant to its authority to enforce the HIPAA rules regarding privacy, security, and breach notification. The Office for Civil Rights issued a request for information regarding the Company’s response to the incident and the Company’s compliance with HIPAA rules, to which the Company responded. The Office for Civil Rights may issue additional requests for information and documentation. In connection with its investigation, the Office for Civil Rights may, among other measures, seek to impose civil monetary penalties against LivaNova and seek to require that the Company implement a corrective action plan. Furthermore, the Company has received, and may receive in the future, additional government requests for information about the incident, to which LivaNova will respond. For example, the Italian data protection authority requested that LivaNova provide certain information regarding the incident, and the Company responded to the request. On September 29, 2025, the Italian data protection authority closed its inquiry.
Other Matters
Additionally, LivaNova is the subject of various pending or threatened legal actions and proceedings that arise in the ordinary course of LivaNova’s business. These matters are subject to many uncertainties and outcomes that are not predictable and that may not be known for extended periods of time. Since the outcome of these matters cannot be predicted with certainty, the costs associated with them could have a material adverse effect on LivaNova’s consolidated results of operations, financial position, or liquidity.
Note 6. Stockholders’ Equity
The tables below present the condensed consolidated statements of stockholders’ equity as of and for the three and nine months ended September 30, 2025 and 2024 (in thousands):
Ordinary Shares
Ordinary Shares - Amount
Additional Paid-In Capital
Treasury Stock
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Total Stockholders’ Equity
June 30, 2025
55,499

$
84,521

$
2,234,777

$
(
1,161
)
$
8,113

$
(
1,203,411
)
$
1,122,839

Stock-based compensation plans
4

(
1
)
10,247

(
34
)
— 
— 
10,212

Net income
— 
— 
— 
— 
— 
26,784

26,784

Other comprehensive loss
— 
— 
— 
— 
(
2,605
)
— 
(
2,605
)
September 30, 2025
55,503

$
84,520

$
2,245,024

$
(
1,195
)
$
5,508

$
(
1,176,627
)
$
1,157,230

June 30, 2024
54,404

$
83,070

$
2,204,580

$
(
195
)
$
(
52,819
)
$
(
992,094
)
$
1,242,542

Stock-based compensation plans
2

42

8,352

39

— 
— 
8,433

Net income
— 
— 
— 
— 
— 
32,953

32,953

Other comprehensive income
— 
— 
— 
— 
26,116

— 
26,116

September 30, 2024
54,406

$
83,112

$
2,212,932

$
(
156
)
$
(
26,703
)
$
(
959,141
)
$
1,310,044

19
Ordinary Shares
Ordinary Shares - Amount
Additional Paid-In Capital
Treasury Stock
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Total Stockholders’ Equity
December 31, 2024
54,438

$
83,156

$
2,220,658

$
(
136
)
$
(
80,170
)
$
(
903,250
)
$
1,320,258

Issuance of shares - EBT
1,000

1,290

— 
(
1,290
)
— 
— 
—

Stock-based compensation plans
65

74

24,366

231

— 
— 
24,671

Net loss
— 
— 
— 
— 
— 
(
273,377
)
(
273,377
)
Other comprehensive income
— 
— 
— 
— 
85,678

— 
85,678

September 30, 2025
55,503

$
84,520

$
2,245,024

$
(
1,195
)
$
5,508

$
(
1,176,627
)
$
1,157,230

December 31, 2023
53,942

$
82,533

$
2,189,517

$
(
55
)
$
(
27,883
)
$
(
966,484
)
$
1,277,628

Issuance of shares - EBT
—

440

— 
(
440
)
— 
— 
—

Stock-based compensation plans
464

139

23,415

339

— 
— 
23,893

Net income
— 
— 
— 
— 
— 
7,343

7,343

Other comprehensive income
— 
— 
— 
— 
1,180

— 
1,180

September 30, 2024
54,406

$
83,112

$
2,212,932

$
(
156
)
$
(
26,703
)
$
(
959,141
)
$
1,310,044

The tables below present the changes in AOCI, net of tax, for the nine months ended September 30, 2025 and 2024 (in thousands):
Foreign Currency Translation Adjustments 
(1)
December 31, 2024
$
(
80,170
)
Other comprehensive income before reclassifications, before tax
85,678

Tax expense
—

Other comprehensive income before reclassifications, net of tax
85,678

Net current-period other comprehensive income, net of tax
85,678

September 30, 2025
$
5,508

(1)
Taxes were not provided for foreign currency translation adjustments, as translation adjustments are related to earnings that are intended to be reinvested in the countries where earned.
Foreign Currency Translation Adjustments 
(1)
December 31, 2023
$
(
27,883
)
Other comprehensive income before reclassifications, before tax
1,180

Tax expense
—

Other comprehensive income before reclassifications, net of tax
1,180

Net current-period other comprehensive income, net of tax
1,180

September 30, 2024
$
(
26,703
)
(1)
Taxes were not provided for foreign currency translation adjustments, as translation adjustments are related to earnings that are intended to be reinvested in the countries where earned.
Note 7. Stock-Based Incentive Plans 
Stock-Based Plans
On June 11, 2025, the Company’s shareholders approved the 2025 Director Incentive Plan and the Second A&R 2022 Plan. The 2025 Director Incentive Plan provides equity-based compensation to non-executive directors by making available a total of 
20
300,000
 shares for awards granted on or after the date on which the 2025 Director Incentive Plan was approved by the Company’s shareholders. The 2025 Director Incentive Plan is intended to be the successor to the 2015 Plan. No further awards may be made under the 2015 Plan, although any outstanding awards under the 2015 Plan will continue to remain in full force and effect. The Second A&R 2022 Plan provides for an aggregate of 
2,200,000
 shares that can be issued pursuant to awards granted on or after the date on which the Second A&R 2022 Plan was approved by the Company’s shareholders. The other terms of the Second A&R 2022 Plan, including its expiration date, remain unchanged from the A&R 2022 Plan. As of September 30, 2025, under the 2025 Director Incentive Plan, there were 
259,423
 shares available for future grants to LivaNova’s non-executive directors, and under the Second A&R 2022 Plan, there were 
2,297,696
 shares available for future grants to LivaNova’s employees.
For the nine months ended September 30, 2025, LivaNova issued stock-based compensatory awards to its employees and Board of Directors with terms approved by the Compensation and Human Capital Management Committee of LivaNova’s Board of Directors and LivaNova’s Board of Directors, respectively. The employee awards with service conditions generally vest ratably over 
three years
 for RSUs and 
four years
 for SARs, and are subject to forfeiture unless service conditions are met. The employee market performance-based awards that were issued generally cliff vest after 
three years
, subject to the rank of LivaNova’s total shareholder return for the 
three-year
 period ending December 31, 2027, relative to the total shareholder returns of the S&P Healthcare Equipment Select Industry Index. The employee adjusted free cash flow and return on invested capital operating performance-based awards that were issued generally cliff vest after 
three years
, subject to the achievement of certain thresholds of cumulative results for the 
three-year
 period ending December 31, 2027. The Board of Director RSU awards with service conditions generally cliff vest at 
one year
. Compensation expense related to awards granted during 2025 for the three and nine months ended September 30, 2025 was $
3.7
 million and $
6.0
 million, respectively.
Stock-Based Compensation Expense
The following table presents the amounts of stock-based compensation expense recognized in LivaNova’s condensed consolidated statements of income (loss) by type of arrangement (in thousands):
Three Months Ended September 30,
Nine Months Ended September 30,
2025
2024
2025
2024
Service-based RSUs
$
4,715

$
4,288

$
12,784

$
13,662

Service-based SARs
3,494

3,480

9,628

10,003

Market performance-based RSUs
629

257

1,558

1,303

Operating performance-based RSUs
748

255

2,030

1,119

Employee share purchase plan
361

279

904

897

$
9,947

$
8,559

$
26,904

$
26,984

Stock-based compensation agreements issued for the nine months ended September 30, 2025, representing potential shares and their weighted average grant date fair values by type, are as follows (shares in thousands, fair value in dollars):
Nine Months Ended September 30, 2025
Shares
Weighted Average Grant Date Fair Value
Service-based SARs
1,038

$
17.87

Service-based RSUs
566

39.98

Market performance-based RSUs
82

41.67

Operating performance-based RSUs
93

39.98

Note 8. Income Taxes
LivaNova PLC is a resident in the UK. LivaNova’s effective income tax rate fluctuates based on, among other factors, changes in pre-tax income in countries with varying statutory tax rates, discrete tax items, valuation allowances, tax credits and incentives, unrecognized tax benefits associated with uncertain tax positions, and tax laws. LivaNova’s tax returns are periodically audited or subjected to review by tax authorities. The Company operates in multiple jurisdictions worldwide and assesses the recoverability of its deferred tax assets for each period and jurisdiction by considering whether it is more likely than not that all or a portion of the deferred tax assets will not be realized. The Company considers all available evidence (both positive and negative) in determining whether a valuation allowance is required. Depending on operating results in the future, a 
21
release of a valuation allowance could occur within the next 12 months. The timing and amount of the valuation allowance release could vary based on the Company’s assessment of all available evidence.
LivaNova’s effective income tax rate for the three and nine months ended September 30, 2025 was 
21.0
% and (
10.0
)%, respectively, compared to 
25.9
% and 
76.9
% for the three and nine months ended September 30, 2024, respectively. The changes in the effective tax rates for the three and nine months ended September 30, 2025, compared to the prior year periods, were primarily attributable to year-over-year changes in income before tax in countries with varying statutory tax rates, certain discrete tax items, including the SNIA environmental liability, and changes in valuation allowances.
The OBBBA was enacted in the U.S. on July 4, 2025 and includes significant provisions, such as the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act, modifications to the international tax framework, and the restoration of favorable tax treatment for certain business provisions. The legislation has multiple effective dates, with certain provisions effective in 2025 and others in 2026. LivaNova has accounted for the relevant changes effective for the 2025 tax year within its annual effective tax rate and continues to evaluate certain provisions that will take effect beginning in 2026, which may or may not affect the Company’s 2025 tax return elections. 
LivaNova is subject to income taxes as well as non-income-based taxes in the U.S., the UK, the EU, and various other jurisdictions. LivaNova will continue to monitor developments globally that may impact the Company’s operations.
Note 9. Income (Loss) Per Share 
The following table presents basic and diluted income (loss) per share:
Three Months Ended September 30,
Nine Months Ended September 30,
2025
2024
2025
2024
Basic income (loss) per share
$
0.49

$
0.61

$
(
5.01
)
$
0.14

Diluted income (loss) per share
0.49

0.60

(
5.01
)
0.13

The following table presents the reconciliations of net income (loss) and weighted average shares outstanding used in the calculations of basic and diluted income (loss) per share (in thousands):
Three Months Ended September 30,
Nine Months Ended September 30,
2025
2024
2025
2024
Numerator 
(1)
:
Net income (loss) - basic and diluted
$
26,784

$
32,953

$
(
273,377
)
$
7,343

Denominator:
Weighted average shares outstanding - basic
54,630

54,352

54,529

54,194

Add: Dilutive effect of share-based compensation and convertible debt instruments 
(1) (2)
523

233

—

332

Weighted average shares outstanding - diluted
55,153

54,585

54,529

54,526

(1)
For the three and nine months ended September 30, 2025, the 2029 Notes were outstanding and potentially dilutive securities, but were excluded from the computation of diluted income (loss) per share because their effect would have been anti-dilutive.
(2)
Excluded from the computation of diluted income (loss) per share were shares underlying stock options, SARs, and RSUs totaling 
0.5
 million and 
3.1
 million for the three months ended September 30, 2025 and 2024, respectively, and 
2.6
 million and 
2.8
 million for the nine months ended September 30, 2025 and 2024, respectively, because to include them would have been anti-dilutive under the treasury stock method.
Note 10. Geographic and Segment Information 
Segment Information
LivaNova identifies operating segments based on how it manages, evaluates, and internally reports its business activities to allocate resources, develop and execute its strategy, and assess performance. LivaNova has 
two
 reportable segments: Cardiopulmonary and Neuromodulation. Net revenue of the Company’s reportable segments includes revenues from the sale of products developed, manufactured, and distributed by each segment, as well as from services related to certain products.
22
LivaNova’s Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including HLMs, oxygenators, autotransfusion systems, perfusion tubing systems, cannulae, and other related accessories, and provides services related to certain of these products.
LivaNova’s Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver neuromodulation therapy for treating DRE and DTD. Neuromodulation products include the VNS Therapy System, which consists of an implantable pulse generator, a lead that connects the generator to the vagus nerve, and other accessories. It also includes the development and management of clinical testing of LivaNova’s aura6000 System for treating OSA.
LivaNova operates under 
three
 geographic regions: U.S., Europe, and Rest of World. 
The following table presents net revenue by operating segment and geographic region (in thousands):
Three Months Ended September 30,
Nine Months Ended September 30,
2025
2024
2025
2024
Cardiopulmonary
United States
$
71,946

$
62,504

$
204,023

$
177,954

Europe 
(1)
50,052

40,894

143,605

120,387

Rest of World 
(1)
81,220

68,841

231,182

203,503

203,218

172,239

578,810

501,844

Neuromodulation
United States
118,390

112,906

343,950

330,518

Europe 
(1)
14,521

11,922

47,445

40,919

Rest of World 
(1)
16,614

15,033

48,693

45,172

149,525

139,861

440,088

416,609

Other Revenue 
(2)
5,010

6,020

8,234

13,154

Totals 
(3)
United States
190,447

179,828

548,085

519,985

Europe 
(1)
67,683

52,815

194,160

158,414

Rest of World 
(1)
99,623

85,477

284,887

253,208

$
357,753

$
318,120

$
1,027,132

$
931,607

(1)
“Europe” includes the UK, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, and Denmark. Excluding Europe and the U.S., “Rest of World” includes all other countries where LivaNova operates. 
(2)
“Other Revenue” includes rental and site services income not allocated to segments. In addition, for the three and nine months ended September 30, 2024, “Other Revenue” includes revenue from the Company’s former ACS reportable segment.
(3)
No single customer represented over 10% of the Company’s consolidated net revenue. No country’s net revenue exceeded 10% of the Company’s consolidated net revenue except for the U.S. 
LivaNova defines segment income as operating income before restructuring expense, amortization of intangible assets, the Saluggia site provision, merger and integration expense, and other income and expense not allocated to segments. Other income and expense not allocated to segments primarily includes corporate expense, rental income, and the results of LivaNova’s former ACS reportable segment. LivaNova’s CODM is the Company’s CEO, who is regularly provided the results comprising segment income to make strategic business decisions, including, but not limited to, evaluation of the Company’s business portfolio, R&D investment decisions, and consideration of the Company’s organizational structure.
23
The following table presents a reconciliation of segment income to consolidated income (loss) before tax (in thousands):
Three Months Ended September 30,
Nine Months Ended September 30,
2025
2024
2025
2024
Cardiopulmonary
$
24,698

$
21,669

$
80,796

$
56,007

Neuromodulation
56,185

49,533

164,558

151,023

Segment income
80,883

71,202

245,354

207,030

Other expense
(
26,871
)
(
35,584
)
(
88,542
)
(
115,000
)
Operating income
54,012

35,618

156,812

92,030

SNIA environmental liability expense
(
1,745
)
—

(
363,815
)
—

Interest expense
 (1)
(
10,863
)
(
15,878
)
(
38,429
)
(
47,303
)
Loss on debt extinguishment
—

—

(
2,651
)
(
25,482
)
Foreign exchange and other income/(expense)
(
7,493
)
24,701

(
332
)
12,585

Income (loss) before tax
$
33,911

$
44,441

$
(
248,415
)
$
31,830

(1)
“Interest expense” includes contractual interest expense associated with LivaNova’s short- and long-term financing arrangements and the amortization of debt discount and issuance costs of $
5.9
 million and $
17.3
 million for the three and nine months ended September 30, 2025, respectively, and $
5.5
 million and $
15.7
 million for the three and nine months ended September 30, 2024, respectively.
The following tables present the components of segment income, including significant expenses, of LivaNova’s reportable segments (in thousands):
Cardiopulmonary
Neuromodulation
Three Months Ended September 30,
Three Months Ended September 30,
2025
2024
2025
2024
Net revenue
$
203,218

$
172,239

$
149,525

$
139,861

Less:
Cost of sales
98,088

80,971

12,693

11,385

Selling, general, and administrative
58,580

49,338

49,937

45,529

Research and development
18,108

12,560

30,710

33,414

3T litigation provision
3,744

7,701

—

—

$
24,698

$
21,669

$
56,185

$
49,533

Cardiopulmonary
Neuromodulation
Nine Months Ended September 30,
Nine Months Ended September 30,
2025
2024
2025
2024
Net revenue
$
578,810

$
501,844

$
440,088

$
416,609

Less:
Cost of sales
278,473

243,856

40,848

33,916

Selling, general, and administrative
168,551

146,842

148,604

137,322

Research and development
46,617

38,341

86,078

94,348

3T litigation provision
4,373

16,798

—

—

$
80,796

$
56,007

$
164,558

$
151,023

24
The following table presents assets by reportable segment (in thousands):
September 30, 2025
December 31, 2024
Cardiopulmonary
$
1,018,811

$
900,672

Neuromodulation
639,970

640,956

Other assets 
(1)
898,802

964,761

$
2,557,583

$
2,506,389

(1)
“Other assets” primarily includes corporate assets not allocated to segments.
The following table presents capital expenditures by reportable segment (in thousands):
Three Months Ended September 30,
Nine Months Ended September 30,
2025
2024
2025
2024
Cardiopulmonary
$
9,495

$
7,383

$
23,431

$
18,657

Neuromodulation
4,738

1,379

10,988

2,380

Other capital expenditures 
(1)
9,151

5,318

16,642

13,241

$
23,384

$
14,080

$
51,061

$
34,278

(1)
“Other capital expenditures” primarily includes corporate capital expenditures not allocated to segments.
The following table presents changes in the carrying amount of goodwill by reportable segment for the nine months ended September 30, 2025 (in thousands):
Cardiopulmonary
Neuromodulation
Total
December 31, 2024
$
351,252

$
398,754

$
750,006

Foreign currency adjustments
41,028

—

41,028

September 30, 2025
$
392,280

$
398,754

$
791,034

Geographic Information
The following table presents property, plant, and equipment, net by geographic region (in thousands):
September 30, 2025
December 31, 2024
United States
$
74,296

$
65,170

Europe
129,274

94,394

Rest of World
14,940

10,696

$
218,510

$
170,260

Note 11. Supplemental Financial Information
The following table presents the components of inventories (in thousands):
September 30, 2025
December 31, 2024
Raw materials
$
77,895

$
71,949

Work-in-process
17,971

12,322

Finished goods
71,672

63,295

$
167,538

$
147,566

As of September 30, 2025 and December 31, 2024, inventories included adjustments totaling $
20.7
 million and $
16.4
 million, respectively, to record balances at the lower of cost or net realizable value.
25
The following table presents the components of accrued liabilities and other (in thousands):
September 30, 2025
December 31, 2024
Legal and professional costs
$
18,481

$
17,379

Italian MedTech payback measure
12,255

15,981

Contract liabilities
11,084

10,848

Operating lease liabilities
9,001

9,040

Provisions for agents, returns, and other
4,948

6,744

Royalty accrual
4,660

4,466

Interest payable
3,235

9,479

Current derivative liabilities
1,888

2,915

Research and development costs
1,353

6,167

Restructuring liabilities
—

2,003

Other accrued expenses
25,324

33,463

$
92,229

$
118,485

As of September 30, 2025 and December 31, 2024, contract liabilities totaling $
15.3
 million and $
14.7
 million, respectively, were included in accrued liabilities and other long-term liabilities on the condensed consolidated balance sheets.
The following table presents the items included in foreign exchange and other income/(expense) on the condensed consolidated statements of income (loss) (in thousands):
Three Months Ended September 30,
Nine Months Ended September 30,
2025
2024
2025
2024
Embedded derivative fair value adjustment (2025 Notes) 
(1)
$
(
322
)
$
2,829

$
1,230

$
1,466

Embedded derivative fair value adjustment (2029 Notes) 
(1)
(
16,422
)
18,423

(
12,696
)
10,488

Capped call fair value adjustment (2025 Notes) 
(1)
324

(
1,668
)
(
997
)
(
10,201
)
Capped call fair value adjustment (2029 Notes) 
(1)
6,353

(
2,517
)
4,276

(
2,040
)
Investment revaluation - Ceribell, Inc. 
(2)
—

—

(
3,622
)
—

Impairments of investments 
(3)
(
1,112
)
—

(
1,112
)
(
5,750
)
Interest income
3,899

7,139

14,525

21,497

FX fluctuations
(
613
)
220

(
2,463
)
(
2,885
)
Other
400

275

527

10

$
(
7,493
)
$
24,701

$
(
332
)
$
12,585

(1)
Refer to “Note 3. Fair Value Measurements.”
(2)
During the second quarter of 2025, LivaNova liquidated its investment in Ceribell, Inc., consisting of 
391,952
 common shares, in a series of transactions with an average sales price of $
16.69
 per common share, resulting in net proceeds of $
6.5
 million from an initial investment in 2018 of $
3.0
 million.
(3)
For the three and nine months ended September 30, 2025, LivaNova recorded an impairment of its investment in Highlife S.A.S. For the nine months ended September 30, 2024, LivaNova recorded an impairment related to the Company’s preferred share ownership converting into common stock of ShiraTronics, Inc.
The following table presents a reconciliation of cash, cash equivalents, and restricted cash reported on the condensed consolidated balance sheets that sum to the total of the amounts shown on the condensed consolidated statements of cash flows (in thousands):
September 30, 2025
December 31, 2024
Cash and cash equivalents
$
646,079

$
428,858

Restricted cash 
(1)
—

294,698

$
646,079

$
723,556

(1)
On March 18, 2022, LivaNova PLC, acting through its Italian branch, entered into an Indemnity Letter and an Account Pledge Agreement with Barclays, further to which Barclays issued the SNIA Litigation Guarantee. As security for the SNIA Litigation 
26
Guarantee, LivaNova was required to grant cash collateral to Barclays in USD in an amount equal to the USD equivalent of 
105
% of the amount of the SNIA Litigation Guarantee, calibrated on a biweekly basis, which is presented as restricted cash on the condensed consolidated balance sheet. On March 31, 2025, as a result of the decision by the Italian Supreme Court, the SNIA Litigation Guarantee was terminated, and the restriction on the cash deposit held as collateral was released. For additional information, refer to “Note 5. Commitments and Contingencies.”
Note 12. New Accounting Pronouncements 
The following table presents a description of future adoptions of new ASUs issued by the FASB that may have an impact on LivaNova’s consolidated financial statements when adopted:
Issue Date & Standard
Description
Adoption
Assessment
December 2023 ASU No. 2023-09, 
Income Taxes (Topic 740): Improvements to Income Tax Disclosures
This ASU expands annual income tax disclosures primarily related to the rate reconciliation and income taxes paid.
This ASU will be effective for annual periods beginning after December 15, 2024, on a prospective basis, with early adoption and retrospective application permitted.
LivaNova does not expect this standard will have a material effect on the Company’s consolidated financial statements and related disclosures.
November 2024 ASU No. 2024-03, 
Income Statement—Reporting Comprehensive
Income—Expense Disaggregation Disclosures
(Subtopic 220-40): Disaggregation of Income Statement Expenses
This ASU requires disclosure in the notes to financial statements of additional information disaggregating specific expense categories underlying certain income statement expense line items, including employee compensation, depreciation, and intangible asset amortization, as well as certain other disclosures to provide enhanced transparency into the nature and function of expenses.
This ASU will be effective for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027. This ASU may be applied on either a prospective or retrospective basis, with early adoption permitted.
LivaNova is currently evaluating the effect this standard will have on the Company’s consolidated financial statements and related disclosures.
July 2025 ASU No. 2025-05, 
Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets
This ASU provides a practical expedient related to the estimation of expected credit losses for current accounts receivable and current contract assets arising from transactions accounted for under Topic 606, including those assets acquired in a business combination. The practical expedient permits an entity to assume that current conditions as of the balance sheet date do not change for the remaining life of the current accounts receivable and current contract assets.
This ASU will be effective for annual periods beginning after December 15, 2025, and interim periods within those annual reporting periods, on a prospective basis, with early adoption permitted.
LivaNova is currently evaluating the effect this standard will have on the Company’s consolidated financial statements and related disclosures.
September 2025 ASU No. 2025-06, 
Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for
Internal-Use Software
This ASU updates the cost capitalization threshold for internal-use software development costs by removing all references to software project development stages and providing new guidance on how to evaluate whether the probable-to-complete recognition threshold has been met.
This ASU will be effective for annual periods beginning after December 15, 2027, and interim periods within those annual reporting periods, with early adoption permitted. The transition method may be prospective, modified, or retrospective.
LivaNova is currently evaluating the effect this standard will have on the Company’s consolidated financial statements and related disclosures.
Note 13. Revision of Previously Issued Financial Statements 
As discussed in “Note 1. Unaudited Condensed Consolidated Financial Statements,” the Company identified and corrected an immaterial error related to the classification of certain employee costs in the Cardiopulmonary segment between cost of sales and selling, general, and administrative expense in the consolidated statements of income (loss). 
27
The following tables present a summary of the corrections to the impacted financial statement line items in the Company’s financial statements previously issued in the Annual Report on Form 10-K and unaudited Quarterly Reports on Form 10-Q (in thousands):
Twelve Months Ended December 31, 2024
Twelve Months Ended December 31, 2023
As Previously Reported
Adjustment
As Revised
As Previously Reported
Adjustment
As Revised
Cost of sales
$
382,564

$
17,389

$
399,953

$
382,295

$
15,430

$
397,725

Gross profit
870,873

(
17,389
)
853,484

771,250

(
15,430
)
755,820

Selling, general, and administrative
526,265

(
17,389
)
508,876

518,129

(
15,430
)
502,699

Three Months Ended March 31, 2025
Three Months Ended March 31, 2024
As Previously Reported
Adjustment
As Revised
As Previously Reported
Adjustment
As Revised
Cost of sales
$
96,080

$
4,521

$
100,601

$
87,522

$
4,182

$
91,704

Gross profit
220,775

(
4,521
)
216,254

207,390

(
4,182
)
203,208

Selling, general, and administrative
133,667

(
4,521
)
129,146

129,863

(
4,182
)
125,681

Three Months Ended September 30, 2024
Nine Months Ended September 30, 2024
As Previously Reported
Adjustment
As Revised
As Previously Reported
Adjustment
As Revised
Cost of sales
$
92,856

$
4,235

$
97,091

$
280,088

$
12,404

$
292,492

Gross profit
225,264

(
4,235
)
221,029

651,519

(
12,404
)
639,115

Selling, general, and administrative
131,661

(
4,235
)
127,426

390,642

(
12,404
)
378,238

The following tables present a summary of the corrections to the impacted Cardiopulmonary disaggregated segment income table line items in “Note 17. Geographic and Segment Information” and “Notre 10. Geographic and Segment Information” previously included in the 2024 Annual Report on Form 10-K and in the unaudited March 31, 2025 Quarterly Report on Form 10-Q, respectively (in thousands):
Twelve Months Ended December 31, 2024
Twelve Months Ended December 31, 2023
As Previously Reported
Adjustment
As Revised
As Previously Reported
Adjustment
As Revised
Cost of sales
$
316,937

$
17,389

$
334,326

$
290,929

$
15,430

$
306,359

Selling, general, and administrative
217,136

(
17,389
)
199,747

207,001

(
15,430
)
191,571

Three Months Ended March 31, 2025
Three Months Ended March 31, 2024
As Previously Reported
Adjustment
As Revised
As Previously Reported
Adjustment
As Revised
Cost of sales
$
80,399

$
4,521

$
84,920

$
72,097

$
4,182

$
76,279

Selling, general, and administrative
58,480

(
4,521
)
53,959

50,745

(
4,182
)
46,563

28
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion and analysis should be read in conjunction with the condensed consolidated financial statements and related notes, which appear elsewhere in this Report, and with LivaNova’s 2024 Form 10-K. LivaNova’s discussion and analysis may contain forward-looking statements that involve risks and uncertainties. The Company’s actual results may differ materially from those anticipated in these forward-looking statements as a result of certain factors, including those set forth under “Risk Factors” in Part I, Item 1A. of LivaNova’s 2024 Form 10-K, as updated and supplemented by LivaNova’s Quarterly Reports on Form 10-Q, including in Part II, Item 1A. and elsewhere in this Report. The accompanying unaudited condensed consolidated financial statements of LivaNova and its consolidated subsidiaries have been prepared in accordance with U.S. GAAP on an interim basis. The capitalized terms used below are defined in the “Definitions” section and in the notes to LivaNova’s condensed consolidated financial statements in this Report.
Description of the Business
LivaNova PLC is a market-leading global medical technology company. The Company designs, develops, manufactures, markets, and sells products and therapies that are consistent with LivaNova’s mission to provide hope for patients and their families through medical technologies, delivering life-changing solutions in select neurological and cardiac conditions. LivaNova is a public limited company organized under the laws of England and Wales and is headquartered in London, England. LivaNova’s ordinary shares are listed for trading on the Nasdaq under the symbol “LIVN.” 
Macroeconomic Environment and Global Supply Chain 
The current macroeconomic environment, including FX volatility, inflationary pressures, and geopolitical instability, and global supply chain challenges have impacted and may continue to impact LivaNova’s business, results of operations, cash flows, and financial condition. Furthermore, LivaNova continues to experience logistical, capacity, and labor constraints. However, to date, the Company’s supply of raw materials and the production and distribution of finished products have not been materially affected. The Company continues to respond to such challenges. While LivaNova has business continuity plans in place, the impact of the ongoing challenges the Company is navigating, along with their potential escalation, may adversely affect its business. 
In addition, the impact that the imposition of tariffs and changes to global trade policies could have on the Company’s results of operations is uncertain. A significant number of LivaNova’s Cardiopulmonary products and component parts are sourced and produced outside of the U.S., including in Italy and Germany. Similarly, LivaNova manufactures its Neuromodulation products in the U.S., which are then often distributed internationally. For additional information, see (1) “Part II, Item 1A. Risk Factors” and elsewhere in this Report and the Company’s other Quarterly Reports on Form 10-Q and (2) “Part I, Item 1A. Risk Factors” of the Company’s 2024 Form 10-K.
Cybersecurity Incident
As previously disclosed, in November 2023, LivaNova detected a cybersecurity incident that resulted in a disruption of portions of the Company’s information technology systems. As a result, the Company engaged external cybersecurity experts, coordinated with law enforcement, implemented remediation measures, and notified affected individuals and regulators as required by applicable law. The incident was contained, and the Company’s mitigation efforts are considered complete. For further discussion on legal and regulatory developments, refer to “Note 5. Commitments and Contingencies” in the condensed consolidated financial statements in this Report. 
Through September 30, 2025, LivaNova incurred direct costs totaling $13.1 million in connection with this cybersecurity incident, including $0.1 million and $2.5 million for the three months ended September 30, 2025 and 2024, respectively, and $1.5 million and $8.2 million for the nine months ended September 30, 2025 and 2024, respectively. The total direct costs incurred primarily include external cybersecurity expert and legal fees, system restoration costs, and $1.2 million related to a class action settlement, and do not include business interruption losses. The Company may incur additional costs related to this incident in the future. LivaNova maintains insurance, including cyber insurance, which is subject to certain retentions and policy limitations that will likely limit the amount that the insurers may reimburse the Company. LivaNova has filed claims for insurance reimbursement of direct costs and business interruption losses related to this incident and has submitted additional claims and supplemental requests for reimbursement as new costs have been incurred. Through September 30, 2025, LivaNova has received $9.6 million, including $6.2 million in reimbursement of direct costs and $3.4 million in reimbursement of business interruption losses. For the nine months ended September 30, 2025, LivaNova received $1.2 million in reimbursement of direct costs. The Company’s insurance coverage may be insufficient to cover all costs and expenses related to this cybersecurity incident or may be unavailable to cover all costs and expenses related to this cybersecurity incident.
29
Business Segments
LivaNova has two reportable segments: Cardiopulmonary and Neuromodulation. For additional information regarding LivaNova’s reportable segments, historical financial information, and its methodology for the presentation of financial results, refer to the condensed consolidated financial statements and accompanying notes of this Report.
Cardiopulmonary
LivaNova’s Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including HLMs, oxygenators, autotransfusion systems, perfusion tubing systems, cannulae, and other related accessories, and provides services related to certain of these products. In particular, the Cardiopulmonary segment includes the Essenz Perfusion System, the Company’s next-generation HLM with an embedded patient monitor for tailored patient care strategies and sensing technology for data-driven decision-making during cardiopulmonary bypass procedures. 
Information on the Cardiopulmonary segment that could potentially impact LivaNova’s condensed consolidated financial statements and related disclosures is incorporated by reference to “Note 5. Commitments and Contingencies: Product Liability Litigation” in the condensed consolidated financial statements in this Report.
Neuromodulation
LivaNova’s Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver neuromodulation therapy for treating DRE and DTD. 
Epilepsy
LivaNova’s principal Neuromodulation product, the VNS Therapy System, is designed as an adjunctive treatment to reduce seizures in people with DRE, and is approved in many jurisdictions globally, including in the U.S. for patients 4 years of age or older with partial onset seizures. The VNS Therapy System consists of an implantable pulse generator and connective lead that stimulates the left vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals that enable a treating physician to set parameters for a patient’s pulse generator. The lead does not need to be removed to replace a generator with a depleted battery.
In June 2025, the Company announced the completion of the CORE-VNS study, evaluating comprehensive outcomes of real-world evidence for more than 800 people with drug-resistant epilepsy treated with VNS Therapy worldwide. With the clinical study report now complete, the final 36-month data further validate the effectiveness of VNS Therapy for severe focal seizures in both children and adults with DRE and demonstrate early and lasting outcomes of adjunctive VNS Therapy on severe focal seizures in pediatric and adult patients. Additionally, LivaNova announced that 24-month data on generalized tonic-clonic seizures in people with DRE from the CORE-VNS three-year study have been published in 
Epilepsia
.
Obstructive Sleep Apnea
The Neuromodulation segment is also engaged in the development and management of clinical testing for LivaNova’s aura6000 System for treating OSA. The aura6000 device stimulates the hypoglossal nerve, which engages specific tongue and palate muscles to open the airway while a patient sleeps. 
In May 2025, the Company announced the 12-month top-line data from its OSPREY clinical trial, evaluating outcomes with the aura6000 System for the treatment of moderate to severe OSA. At 12 months of therapy, the treatment arm responder rate was 65%, with responders defined as those who realized at least a 50% improvement from the baseline AHI and an AHI value below 20. When comparing baseline median values to six and 12 months of therapy (assessed at the seven- and 13-month follow-up visits, respectively), OSPREY subjects showed significant reductions in AHI and ODI over time. Further, after 12 months of treatment, OSPREY subjects in the device stimulation group experienced clinically meaningful improvements in the Epworth Sleepiness Scale and the Functional Outcomes of Sleep Questionnaire.
Depression
The Neuromodulation segment also includes 
the VNS Therapy System for the adjunctive treatment of chronic or recurrent depression for patients 18 years or older who are experiencing a major depressive episode and have not had an adequate r
esponse to four or more antidepressant treatments. LivaNova initiated the RECOVER clinical study, a CMS-approved, double-blind, randomized, placebo-controlled trial, in connection with its request that CMS reconsider its previous non-coverage determination.
In June 2024, the Company announced the preliminary results for the unipolar patient cohort of the RECOVER clinical study, assessing the use of VNS Therapy for TRD. The study did not meet its primary endpoint for the unipolar cohort; however, 
30
statistical significance and clinically meaningful benefit were achieved in select secondary endpoints as detailed in two articles published in a peer-reviewed journal in December 2024. Three subsequent peer-reviewed articles, published between March and July 2025, evaluated the sensitivity of symptom measures and demonstrated that symptoms, daily function, and quality of life, taken together as a composite or “tripartite” measure, present a more complete picture of treatment effectiveness in patients with DTD and can inform clinical decision-making by identifying patient features that may be associated with greater benefit from adjunctive active VNS Therapy, such as patients who received prior interventional treatments. Together, the Company believes these articles support the use of VNS Therapy in patients with DTD. 
In June 2025, the Company announced that it had initiated the process with CMS to seek reconsideration of national Medicare coverage for VNS Therapy in unipolar patients with TRD. 
Critical Accounting Estimates 
For a discussion of LivaNova’s critical accounting estimates, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in the 2024 Form 10-K. For the nine months ended September 30, 2025, there were no material changes to the application of critical accounting policies and estimates previously disclosed in LivaNova’s 2024 Form 10-K. 
Results of Operations
The following table presents LivaNova’s condensed consolidated results of operations (in thousands):
Three Months Ended September 30,
Nine Months Ended September 30,
2025
2024
2025
2024
Net revenue
$
357,753 
$
318,120 
$
1,027,132 
$
931,607 
Cost of sales 
(1)
112,898 
97,091 
327,035 
292,492 
Gross profit 
(1)
244,855 
221,029 
700,097 
639,115 
Operating expenses:
Selling, general, and administrative 
(1)
138,522 
127,426 
405,448 
378,238 
Research and development
48,577 
48,805 
133,641 
139,206 
Other operating expense
3,744 
9,180 
4,196 
29,641 
Operating income
54,012 
35,618 
156,812 
92,030 
SNIA environmental liability expense
(1,745)
— 
(363,815)
— 
Interest expense
(10,863)
(15,878)
(38,429)
(47,303)
Loss on debt extinguishment
— 
— 
(2,651)
(25,482)
Foreign exchange and other income/(expense)
(7,493)
24,701 
(332)
12,585 
Income (loss) before income tax
33,911 
44,441 
(248,415)
31,830 
Income tax expense
7,114 
11,525 
24,921 
24,469 
(Loss) income from equity method investments
(13)
37 
(41)
(18)
Net income (loss)
$
26,784 
$
32,953 
$
(273,377)
$
7,343 
(1)
The above table presents revised financial results, as discussed in “Note 1. Unaudited Condensed Consolidated Financial Statements” and “Note 13. Revision of Previously Issued Financial Statements” in the condensed consolidated financial statements in this Report.
31
Net Revenue
The following table presents net revenue by operating segment and geographic region (in thousands, except for percentages):
Three Months Ended September 30,
Nine Months Ended September 30,
2025
2024
% Change
2025
2024
% Change
Cardiopulmonary
United States
$
71,946 
$
62,504 
15.1 
%
$
204,023 
$
177,954 
14.6 
%
Europe 
(1)
50,052 
40,894 
22.4 
%
143,605 
120,387 
19.3 
%
Rest of World 
(1)
81,220 
68,841 
18.0 
%
231,182 
203,503 
13.6 
%
203,218 
172,239 
18.0 
%
578,810 
501,844 
15.3 
%
Neuromodulation
United States
118,390 
112,906 
4.9 
%
343,950 
330,518 
4.1 
%
Europe 
(1)
14,521 
11,922 
21.8 
%
47,445 
40,919 
15.9 
%
Rest of World 
(1)
16,614 
15,033 
10.5 
%
48,693 
45,172 
7.8 
%
149,525 
139,861 
6.9 
%
440,088 
416,609 
5.6 
%
Other Revenue 
(2)
5,010 
6,020 
(16.8)
%
8,234 
13,154 
(37.4)
%
Totals
United States
190,447 
179,828 
5.9 
%
548,085 
519,985 
5.4 
%
Europe 
(1) 
67,683 
52,815 
28.2 
%
194,160 
158,414 
22.6 
%
Rest of World 
(1)
99,623 
85,477 
16.5 
%
284,887 
253,208 
12.5 
%
$
357,753 
$
318,120 
12.5 
%
$
1,027,132 
$
931,607 
10.3 
%
(1)
“Europe” includes the UK, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, and Denmark. Excluding Europe and the U.S., “Rest of World” includes all other countries where LivaNova operates. 
(2)
“Other Revenue” includes rental and site services income not allocated to segments. In addition, for the three and nine months ended September 30, 2024, “Other Revenue” includes revenue from the Company’s former ACS reportable segment.
The following table presents segment income 
(1)
 (in thousands, except for percentages):
Three Months Ended September 30,
Nine Months Ended September 30,
2025
2024
% Change
2025
2024
% Change
Cardiopulmonary
$
24,698 
$
21,669 
14.0 
%
$
80,796 
$
56,007 
44.3 
%
Neuromodulation 
56,185 
49,533 
13.4 
%
164,558 
151,023 
9.0 
%
$
80,883 
$
71,202 
13.6 
%
$
245,354 
$
207,030 
18.5 
%
(1)
For a reconciliation of segment income to consolidated income (loss) before tax, refer to “Note 10. Geographic and Segment Information” in the condensed consolidated financial statements in this Report.
Cardiopulmonary
Cardiopulmonary net revenue for the three and nine months ended September 30, 2025 increased 18.0% to $203.2 million and 15.3% to $578.8 million, respectively, compared to the three and nine months ended September 30, 2024, with growth across all regions, driven by Essenz

Perfusion System sales and strong consumables demand.
Cardiopulmonary segment income for the three and nine months ended September 30, 2025 was $24.7 million and $80.8 million, respectively, compared to segment income of $21.7 million and $56.0 million for the three and nine months ended September 30, 2024, respectively. These increases in segment income primarily resulted from increases in net revenue, as described above, as well as decreases in the amounts recorded for the litigation provision related to LivaNova’s 3T Heater-Cooler device of $4.0 million and $12.4 million for the three- and nine-month comparative periods, respectively.
Neuromodulation
Neuromodulation net revenue for the three and nine months ended September 30, 2025 increased 6.9% to $149.5 million and 5.6% to $440.1 million, respectively, compared to the three and nine months ended September 30, 2024, with growth across all regions.
32
Neuromodulation segment income for the three and nine months ended September 30, 2025 was $56.2 million and $164.6 million, respectively, compared to $49.5 million and $151.0 million for the three and nine months ended September 30, 2024, respectively. These increases in segment income primarily resulted from increases in net revenue, as described above, as well as net decreases in R&D expense for the three- and nine-month comparative periods, primarily resulting from $9.7 million and $19.1 million reductions in costs associated with the Company’s DTD program, respectively.
Cost of Sales and Expenses
The following table presents costs and expenses as a percentage of net revenue:
Three Months Ended September 30,
Nine Months Ended September 30,
2025
2024
Change
2025
2024
Change
Cost of sales 
(1)
31.6 
%
30.5 
%
1.1 
%
31.8 
%
31.4 
%
0.4 
%
Selling, general, and administrative 
(1)
38.7 
%
40.1 
%
(1.4)
%
39.5 
%
40.6 
%
(1.1)
%
Research and development
13.6 
%
15.3 
%
(1.7)
%
13.0 
%
14.9 
%
(1.9)
%
Other operating expense
1.0 
%
2.9 
%
(1.9)
%
0.4 
%
3.2 
%
(2.8)
%
(1)
The above table and commentary below present revised financial results, as discussed in “Note 1. Unaudited Condensed Consolidated Financial Statements” and “Note 13. Revision of Previously Issued Financial Statements” in the condensed consolidated financial statements in this Report.
Cost of Sales
Cost of sales primarily consists of direct labor, allocated overhead, and the acquisition of raw materials and components.
Cost of sales as a percentage of net revenue was 31.6% and 31.8% for the three and nine months ended September 30, 2025, respectively, representing increases of 1.1 and 0.4 percentage points compared to the three and nine months ended September 30, 2024, respectively, primarily resulting from accruals related to increases in the fair value of the ImThera sales-based contingent consideration arrangement of $1.2 million and $3.1 million for the three- and nine-month comparative periods, respectively, as well as unfavorable product mix. 
Selling, General, and Administrative Expense
SG&A expense primarily consists of sales, marketing, general, and administrative activities. 
SG&A expense as a percentage of net revenue was 38.7% and 39.5% for the three and nine months ended September 30, 2025, respectively, representing decreases of 1.4 and 1.1 percentage points compared to the three and nine months ended September 30, 2024, respectively, primarily due to the decline in costs associated with the November 2023 cybersecurity incident and the impact of related insurance recoveries.
Research and Development Expense
R&D expense primarily consists of product design and development efforts, clinical study programs, and regulatory activities.
R&D expense as a percentage of net revenue was 13.6% and 13.0% for the three and nine months ended September 30, 2025, respectively, representing decreases of 1.7 and 1.9 percentage points compared to the three and nine months ended September 30, 2024, respectively, primarily due to reductions in costs associated with the Company’s DTD program of $9.7 million and $19.1 million, respectively.
Other Operating Expense
Other operating expense primarily consists of charges related to LivaNova’s 3T Heater-Cooler device litigation provision and restructuring expense.
Other operating expense as a percentage of net revenue was 1.0% and 0.4% for the three and nine months ended September 30, 2025, respectively, representing decreases of 1.9 and 2.8 percentage points compared to the three and nine months ended September 30, 2024, respectively. The decreases were due to decreases of $4.0 million and $12.4 million in the amount recorded for the litigation provision related to LivaNova’s 3T Heater-Cooler device for the three- and nine-month comparative periods, respectively, as well as decreases of $1.5 million and $13.0 million in restructuring costs associated with the 2024 Restructuring Plan for the same periods. For additional information, please refer to “Note 5. Commitments and Contingencies” in the condensed consolidated financial statements in this Report. 
33
SNIA Environmental Liability Expense
On March 14, 2025, the Italian Supreme Court issued its decision in response to all of the appeals of the Company and counter-appeals submitted by the Public Administrations. The Italian Supreme Court determined that LivaNova can be held jointly and severally liable for the established liabilities of SNIA at the time of demerger, as well as the environmental liabilities of the demerged company that materialized after the demerger, which are derived from actions performed prior to the demerger. As a result of the decision by the Italian Supreme Court, the Company recorded the SNIA environmental liability expense in the quarter ended March 31, 2025, and has continued to accrue interest since that time. For additional information, please refer to “Note 5. Commitments and Contingencies” in the condensed consolidated financial statements in this Report. 
Loss on Debt Extinguishment
For the nine months ended September 30, 2025, LivaNova incurred a loss on debt extinguishment of $2.7 million associated with the write-off of unamortized debt issuance costs in connection with the early repayment of $200 million on principal borrowings under the Term Facilities in May 2025. For the nine months ended September 30, 2024, LivaNova incurred a loss on debt extinguishment of $25.5 million in connection with the 2025 Notes Repurchase Transaction in March 2024.
Interest Expense
Interest expense decreased to $10.9 million and $38.4 million for the three and nine months ended September 30, 2025, respectively, compared to $15.9 million and $47.3 million for the three and nine months ended September 30, 2024, respectively, primarily due to an early repayment on May 2, 2025 of $200 million on principal borrowings under the Term Facilities, as well as decreases in interest rates, partially offset by an increase in amortization of debt issuance costs. For additional information, refer to “Note 4. Financing Arrangements” in the condensed consolidated financial statements in this Report.
Foreign Exchange and Other Income/(Expense)
Foreign exchange and other income/(expense) consists primarily of gains and losses arising from transactions denominated in a currency different from an entity’s functional currency, FX derivative gains and losses, interest income, changes in the fair value of embedded and capped call derivatives, and gains and losses associated with LivaNova’s investments.
Foreign exchange and other income/(expense) was expense of $7.5 million and $0.3 million for the three and nine months ended September 30, 2025, respectively, compared to income of $24.7 million and $12.6 million for the three and nine months ended September 30, 2024, respectively. For additional information, refer to “Note 11. Supplemental Financial Information” in the condensed consolidated financial statements in this Report.
Income Tax Expense
LivaNova PLC is a resident in the UK. LivaNova’s effective income tax rate fluctuates based on, among other factors, changes in pre-tax income in countries with varying statutory tax rates, discrete tax items, valuation allowances, tax credits and incentives, unrecognized tax benefits associated with uncertain tax positions, and tax laws. LivaNova’s tax returns are periodically audited or subjected to review by tax authorities. The Company operates in multiple jurisdictions worldwide and assesses the recoverability of its deferred tax assets for each period and jurisdiction by considering whether it is more likely than not that all or a portion of the deferred tax assets will not be realized. The Company considers all available evidence (both positive and negative) in determining whether a valuation allowance is required. Depending on operating results in the future, a release of a valuation allowance could occur within the next 12 months. The timing and amount of the valuation allowance release could vary based on the Company’s assessment of all available evidence.
LivaNova’s effective income tax rate for the three and nine months ended September 30, 2025 was 21.0% and (10.0)%, respectively, compared to 25.9% and 76.9% for the three and nine months ended September 30, 2024, respectively. The changes in the effective tax rates for the three and nine months ended September 30, 2025, compared to the prior year periods, were primarily attributable to year-over-year changes in income before tax in countries with varying statutory tax rates, certain discrete tax items, including the SNIA environmental liability, and changes in valuation allowances.
The OBBBA was enacted in the U.S. on July 4, 2025 and includes significant provisions, such as the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act, modifications to the international tax framework, and the restoration of favorable tax treatment for certain business provisions. The legislation has multiple effective dates, with certain provisions effective in 2025 and others in 2026. LivaNova has accounted for the relevant changes effective for the 2025 tax year within its annual effective tax rate and continues to evaluate certain provisions that will take effect beginning in 2026, which may or may not affect the Company’s 2025 tax return elections. 
34
LivaNova is subject to income taxes as well as non-income-based taxes in the U.S., the UK, the EU, and various other jurisdictions. LivaNova will continue to monitor developments globally that may impact the Company’s operations. 
Liquidity and Capital Resources
Based on LivaNova’s current business plan, which includes estimates and assumptions regarding the amount and timing of cash receipts and payments, the Company believes that its sources of liquidity, which primarily consist of cash and cash equivalents, future cash generated from operations, and available borrowings under its revolving credit facility, will be sufficient to fund its uses of liquidity, primarily consisting of day-to-day operating expenses, working capital, capital expenditures, acquisition earnouts, commitments and contingencies, including the SNIA environmental liability, and debt service requirements over the twelve-month period beginning from the issuance date of this Report. From time to time, LivaNova may access debt and/or equity markets to optimize its capital structure, raise additional capital, or increase liquidity, as necessary. LivaNova’s liquidity could be adversely affected by the factors affecting future operating results, including those referred to in “Part I, Item 1A. Risk Factors” in the 2024 Form 10-K, as well as “Note 5. Commitments and Contingencies” in the condensed consolidated financial statements in this Report. 
LivaNova’s operating and working capital obligations primarily consist of liabilities arising in the normal course of business, including inventory supply contracts, the future settlement of derivative instruments, and future lease payments, as well as contingent consideration arrangements resulting from acquisitions and obligations associated with legal and other accruals. 
The following table presents selected financial information related to LivaNova’s liquidity (in thousands):
September 30, 2025
December 31, 2024
Available Short-term Liquidity
Cash and cash equivalents
$
646,079 
$
428,858 
Availability under the 2021 First Lien Credit Agreement
225,000 
225,000 
$
871,079 
$
653,858 
Working Capital
Current assets
$
1,097,149 
$
1,127,186 
Current liabilities
827,588 
392,125 
$
269,561 
$
735,061 
Debt Obligations
Current portion of long-term debt
$
85,423 
$
77,339 
Short-term unsecured borrowing arrangements
17 
665 
Current debt obligations
85,440 
78,004 
Long-term debt obligations 
(1)
349,031 
549,624 
$
434,471 
$
627,628 
(1)
On May 2, 2025, LivaNova made an early repayment of $200 million on principal borrowings under the Term Facilities.
For information on LivaNova’s debt obligations, refer to “Note 4. Financing Arrangements” in the condensed consolidated financial statements in this Report. 
Cash Flows
The following table presents net cash, cash equivalents, and restricted cash provided by (used in) operating, investing, and financing activities and the net (decrease) increase in the balance of cash, cash equivalents, and restricted cash (in thousands):
Nine Months Ended September 30,

2025
2024
Operating activities
$
171,943 
$
104,331 
Investing activities
(42,653)
(37,452)
Financing activities
(222,776)
21,995 
Effect of exchange rate changes on cash, cash equivalents, and restricted cash
16,009 
(170)
Net (decrease) increase in cash, cash equivalents, and restricted cash 
(1)
$
(77,477)
$
88,704 
(1)
On March 31, 2025, as a result of the decision by the Italian Supreme Court, the SNIA Litigation Guarantee was terminated, and the 
35
restriction on the cash deposit held as collateral was released. For additional information, refer to “Note 5. Commitments and Contingencies” in the condensed consolidated financial statements in this Report.
Operating Activities
Cash provided by operating activities for the nine months ended September 30, 2025 increased by $67.6 million compared to the same prior year period, primarily due to higher customer collections resulting from an increase in sales and lower payments related to LivaNova’s 3T Heater-Cooler device litigation provision, as well as restructuring activities, partially offset by an increase in cash outflows for inventories and income taxes.
Investing Activities
Cash used in investing activities for the nine months ended September 30, 2025 increased by $5.2 million compared to the same prior year period, primarily due to an increase in purchases of property, plant, and equipment of $12.1 million, principally related to purchases and development of internal-use software, partially offset by proceeds from the sale of LivaNova’s investment in Ceribell, Inc. of $6.5 million.
Financing Activities
Cash used in financing activities for the nine months ended September 30, 2025 increased by $244.8 million compared to the same prior year period, primarily due to a decrease in proceeds from net debt borrowings and repayments of $255.3 million, partially offset by the payment of $13.8 million related to the ALung contingent consideration arrangement in the prior year period.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
LivaNova is exposed to certain market risks as part of its ongoing business operations, including risks from foreign currency exchange rates, equity price risk, interest rate risks, and concentration of procurement suppliers that could adversely affect LivaNova’s consolidated financial position, results of operations, or cash flows. The Company manages these risks through regular operating and financing activities and, at certain times, derivative financial instruments. Quantitative and qualitative disclosures about these risks are included in this Report in “Part I, Item 1. Financial Statements, Note 2. Derivatives and Risk Management,” “Part I, Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and “Part II, Item 1A. Risk Factors” and in LivaNova’s 2024 Form 10-K in “Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Part I, Item 1A. Risk Factors.” 
ITEM 4. CONTROLS AND PROCEDURES
Disclosure Controls and Procedures
LivaNova maintains a system of disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act. The disclosure controls and procedures are designed to ensure that information required to be disclosed in the Company’s reports filed under the Exchange Act is (i) recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to management, including LivaNova’s CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure. Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives.
Applicable SEC rules require an evaluation of the effectiveness of the Company’s disclosure controls and procedures. LivaNova’s management, under the supervision and with the participation of the Company’s CEO and CFO, evaluated the effectiveness of the design and operation of the Company’s disclosure controls and procedures as of the end of the period covered by this Report. Based on that evaluation, LivaNova’s CEO and CFO concluded that, as of September 30, 2025, the design and operation of the Company’s disclosure controls and procedures were effective to accomplish their objectives at the reasonable assurance level.
Changes in Internal Control Over Financial Reporting
There have been no changes in LivaNova’s internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended September 30, 2025 that have materially affected, or are reasonably likely to materially affect, LivaNova’s internal control over financial reporting.
36
PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
For a description of LivaNova’s material pending legal and regulatory proceedings and settlements, refer to “Note 5. Commitments and Contingencies” in the Company’s condensed consolidated financial statements included in this Report.
ITEM 1A. RISK FACTORS
There have been no material changes in LivaNova’s risk factors from those disclosed in Part I, Item 1A of the Company’s 2024 Annual Report on Form 10-K, and Part II, Item 1A of the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025.
ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
None.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
None.
ITEM 4. MINE SAFETY DISCLOSURES
Not applicable.
ITEM 5. OTHER INFORMATION
During the quarter ended September 30, 2025, none of the Company’s directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) 
adopted
, 
terminated,
 or modified a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K of the Securities Act).
Disclosure Pursuant to Section 13(r) of the Exchange Act of 1934 
Section 13(r) of the Exchange Act requires issuers to disclose in quarterly reports, among other things, certain types of dealings with Iran and other entities, including transactions or dealings with government-owned entities, even when those activities are lawful and do not involve U.S. persons. Two of LivaNova’s non-U.S. subsidiaries currently sell medical devices, including cardiopulmonary and neuromodulation products, to distributors and a non-governmental organization in Iran to support patient care in that country. LivaNova has limited visibility into the identity of the customers of these distributors and non-governmental organizations in Iran. It is possible that their customers include entities, such as government-owned hospitals or sub-distributors that are owned or controlled directly or indirectly by the Iranian government. However, to the best of its knowledge at this time, LivaNova does not have any contracts or commercial arrangements with the Iranian government or other relevant entities.
LivaNova’s gross revenue and net profits attributable to the above-mentioned Iranian activities were $2.1 million and $1.0 million for the three months ended September 30, 2025, respectively, and $10.8 million and $5.8 million for the nine months ended September 30, 2025, respectively.
LivaNova believes its activities are consistent with applicable law, including U.S., UK, European Union, and other applicable sanctions laws, though such laws are complex and continue to evolve rapidly. The Company intends to continue its business in Iran.
37
ITEM 6. EXHIBITS
The exhibits marked with the asterisk symbol (*) are filed or furnished (for example, in the case of Exhibit 32.1) with this Report. Exhibits marked with the cross symbol (†), if any, are management contracts or compensatory plans or arrangements filed pursuant to Item 601(b)(10)(iii) of Regulation S-K.
Exhibit
Number
Description
31.1*
Certification of the Chief Executive Officer of LivaNova PLC pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*
Certification of the Chief Financial Officer of LivaNova PLC pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1*
Certification of the Chief Executive Officer and Chief Financial Officer of LivaNova PLC pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101*
Interactive Data Files Pursuant to Rule 405 of Regulation S-T formatted in Inline XBRL: (i) the Condensed Consolidated Statements of Income (Loss) for the three and nine months ended September 30, 2025 and 2024, (ii) the Condensed Consolidated Statements of Comprehensive Income (Loss) for the three and nine months ended September 30, 2025 and 2024, (iii) the Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024, (iv) the Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2025 and 2024, and (v) the Notes to the Condensed Consolidated Financial Statements
104*
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
38
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.

LIVANOVA PLC

Date: November 5, 2025
By:
/s/ VLADIMIR MAKATSARIA

Vladimir Makatsaria 

Chief Executive Officer

(Principal Executive Officer)

LIVANOVA PLC

Date: November 5, 2025
By:
/s/ ALEX SHVARTSBURG

Alex Shvartsburg

Chief Financial Officer

(Principal Accounting and Financial Officer)
39